<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurochem Res</journal-id><journal-id journal-id-type="iso-abbrev">Neurochem Res</journal-id><journal-title-group><journal-title>Neurochemical Research</journal-title></journal-title-group><issn pub-type="ppub">0364-3190</issn><issn pub-type="epub">1573-6903</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39644364</article-id><article-id pub-id-type="pmc">PMC11625074</article-id>
<article-id pub-id-type="publisher-id">4281</article-id><article-id pub-id-type="doi">10.1007/s11064-024-04281-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Neuroprotective Potential of Aminonaphthoquinone Derivatives Against Amyloid Beta-Induced Neuronal Cell Death Through Modulation of SIRT1 and BACE1</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Apiraksattayakul</surname><given-names>Setthawut</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Pingaew</surname><given-names>Ratchanok</given-names></name><address><email>ratchanok@g.swu.ac.th</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Prachayasittikul</surname><given-names>Veda</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ruankham</surname><given-names>Waralee</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tantimongcolwat</surname><given-names>Tanawut</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Prachayasittikul</surname><given-names>Virapong</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Prachayasittikul</surname><given-names>Supaluk</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Phopin</surname><given-names>Kamonrat</given-names></name><address><email>kamonrat.php@mahidol.ac.th</email><email>kamonrat.php@mahidol.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01znkr924</institution-id><institution-id institution-id-type="GRID">grid.10223.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0490</institution-id><institution>Center for Research Innovation and Biomedical Informatics, Faculty of Medical Technology, </institution><institution>Mahidol University, </institution></institution-wrap>Bangkok, 10700 Thailand </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04718hx42</institution-id><institution-id institution-id-type="GRID">grid.412739.a</institution-id><institution-id institution-id-type="ISNI">0000 0000 9006 7188</institution-id><institution>Department of Chemistry, Faculty of Science, </institution><institution>Srinakharinwirot University, </institution></institution-wrap>Bangkok, 10110 Thailand </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01znkr924</institution-id><institution-id institution-id-type="GRID">grid.10223.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0490</institution-id><institution>Department of Clinical Microbiology and Applied Technology, Faculty of Medical Technology, </institution><institution>Mahidol University, </institution></institution-wrap>Bangkok, 10700 Thailand </aff></contrib-group><pub-date pub-type="epub"><day>7</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>7</day><month>12</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>50</volume><issue>1</issue><elocation-id>50</elocation-id><history><date date-type="received"><day>23</day><month>6</month><year>2024</year></date><date date-type="rev-recd"><day>19</day><month>10</month><year>2024</year></date><date date-type="accepted"><day>5</day><month>11</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Alzheimer&#x02019;s disease (AD) is characterized by the accumulation of tau protein tangles and amyloid-&#x003b2; (A&#x003b2;) plaques in the central nervous system (CNS), leading to progressive neurodegeneration. Hence, the discovery of disease-modifying agents capable of delaying the progression is essential for effective management. Aminonaphthoquinone (ANQ) is an attractive pharmacophore with various biological effects. This study explores the neuroprotective potentials of ANQ derivatives (<bold>1</bold>&#x02013;<bold>18</bold>) using in vitro models of AD pathology (i.e., A&#x003b2;<sub>42</sub>-induced SH-SY5Y cells). Findings demonstrated that all compounds mitigated A&#x003b2;<sub>42</sub>-induced cellular damage by preserving cell viability and morphology. Among all, four compounds (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) showed potent antioxidant activities as well as abilities to minimize AD-related damages (i.e. decreasing intracellular reactive oxygen species (ROS) production, preserving mitochondrial membrane potential (MMP), protecting membrane damage, and modulating beta-secretase 1 (BACE1) activity) with comparable protective effects to the well-known neuroprotectant, resveratrol (RSV). A molecular docking study indicated these compounds could suitably bind to sirtuin 1 (SIRT1) protein with preferable affinity. Key amino acid residues and key functional groups essential for binding interactions were revealed. Target prediction identified a list of possible AD-related targets of these compounds offering insights into their mechanisms of action and suggesting their multifunctional potentials. Additionally, in silico predictions revealed that these candidates showed favorable drug-like properties. Overall, this study highlighted the therapeutic potential of ANQ derivatives in AD treatment, emphasizing the need for further experimental validation and comprehensive investigations to fully realize their therapeutic benefits.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Alzheimer&#x02019;s disease</kwd><kwd>Aminonaphthoquinone</kwd><kwd>SIRT1</kwd><kwd>Neuroprotection</kwd><kwd>Antioxidant</kwd></kwd-group><funding-group><award-group><funding-source><institution>Mahidol University</institution></funding-source></award-group><open-access><p>Open access funding provided by Mahidol University</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">AD, a neurodegenerative phenomenon afflicting millions globally, represents a leading cause of dementia. AD is characterized by progressive deterioration in memory, cognition, and behavior as well as the accumulation of A&#x003b2; plaques in the brain [<xref ref-type="bibr" rid="CR1">1</xref>]. While the precise origins of this devastating disease remain a mystery, the pivotal role of A&#x003b2;-induced oxidative stress has shed light on its pathogenesis and progression. The buildup of excessive A&#x003b2; accumulated in the brain is likely initiated by an increased enzymatic activity of BACE1, an enzyme that functions for cleaving the amyloid precursor protein to produce A&#x003b2; [<xref ref-type="bibr" rid="CR2">2</xref>]. This excessive A&#x003b2; accumulation is believed to trigger a chain reaction of harmful events within the brain cells, including ROS production and dysregulation of glia, particularly microglia and astrocytes. In AD, glia responds to the accumulation of A&#x003b2; and contributes to neuroinflammation, amyloid plaque formation, and neuronal damage. Moreover, ROS, produced by glia or neuronal cells in response to A&#x003b2;, has been widely recognized for its linkages with mitochondrial dysfunction, cell membrane damage, and neuronal cell death [<xref ref-type="bibr" rid="CR3">3</xref>&#x02013;<xref ref-type="bibr" rid="CR5">5</xref>]. This interconnected pathway highlights the attractive strategies for therapeutic intervention. One promising approach to protect the neurons lies in the attenuation of A&#x003b2;-mediated neurotoxicity. Recently, the potential of low-dose BACE1 inhibitors was revealed to lower the levels of A&#x003b2;<sub>40</sub> and A&#x003b2;<sub>42</sub> by 30%, preventing the initial amyloidogenic cleavage and avoiding side effects [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. Consequently, there is a renewed emphasis on developing more selective but less toxic BACE1 inhibitors used in pre-symptomatic stages in patients with AD. Even BACE1 might not be considered a fundamental player in the progression of AD, nor a key therapeutic target. But BACE1 inhibitor still showed potential as an AD therapeutic agent. Combining with other pharmacological actions could lead to the development of effective neuroprotective agents for preventing AD progression.</p><p id="Par3">The continual increase in AD prevalence indicates the urgent need for the discovery of novel therapeutics. Currently, available drugs are symptomatic drugs incapable of delaying the progression of AD. Despite decades of extensive research efforts, successful disease-modifying medicines for AD remain elusive [<xref ref-type="bibr" rid="CR1">1</xref>]. Accordingly, current research attention has been paid to naturally occurring antioxidants due to their opportunistic potentials for multidisciplinary therapeutic benefits in alleviating the pathological features associated with AD [<xref ref-type="bibr" rid="CR8">8</xref>&#x02013;<xref ref-type="bibr" rid="CR10">10</xref>]. Naphthoquinone (NQ) derivatives are commonly found in various plants and are associated with defense mechanisms against microbial and insect threats. NQs are well-known for their redox properties, this unique property makes them valuable templates for the discovery of numerous therapeutic agents (i.e., antioxidant, antimicrobial, anticancer, anti-inflammatory, and neuroprotective agents). Amongst others, ANQs are captivating candidates, the substitution of an amino moiety (-NH<sub>2</sub>) on the NQ core could modify the molecular polarity and hydrogen-bonding capacity of the molecules. ANQs have been reported for various biological activities [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR13">13</xref>]. The existing literature highlights several studies indicating that certain NQ derivatives exhibit neuroprotective effects, particularly in the context of oxidative stress and neuroinflammation, key factors involved in the pathogenesis of AD [<xref ref-type="bibr" rid="CR14">14</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. Notably, some NQ derivatives were reported for their abilities to activate SIRT1 protein [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. SIRT1, a protein known as a deacetylase, plays a crucial role in cellular processes (i.e., DNA repair, stress response, and metabolism). SIRT1 is also considered a crucial player in neuroprotection due to its ability to enhance neuronal survival and functions [<xref ref-type="bibr" rid="CR20">20</xref>&#x02013;<xref ref-type="bibr" rid="CR22">22</xref>]. Accordingly, ANQ is an attractive scaffold with the potential to tackle the complexity of neurodegenerative disorders.</p><p id="Par4">Fast and effective drug discovery is particularly essential for rapidly evolving diseases or conditions with urgent medical needs. Computational approaches are commonly utilized to accelerate the pipeline and increase the success rate in drug development [<xref ref-type="bibr" rid="CR23">23</xref>]. Computational tools have emerged as pivotal strategies to expedite the identification of potential target proteins for novel compounds. In silico target prediction could allow fast and effective target identification in the early stages of development [<xref ref-type="bibr" rid="CR24">24</xref>]. Molecular docking is commonly used to reveal possible binding modes and interactions of the compounds against the target [<xref ref-type="bibr" rid="CR25">25</xref>], which would be beneficial for future design and optimization of the compounds. Poor pharmacokinetics (drug-likeness) and severe toxicities of the compounds are key factors rendering the failures in drug development, especially the late-stage occurring ones. Hence, the prediction of these properties within an initial phase of development is highly recommended [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par5">In this study, a series of 18 ANQs (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) was previously reported by our research group [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Some compounds elicited promising anticancer activities, while most of them displayed low cytotoxicity or non-cytotoxicity to normal cell lines. Additionally, various NQ derivatives have been shown to possess neuroprotective effects and SIRT1 activators [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>]. This promising activity highlights their potentials for therapeutic applications beyond cancer treatment. Herein, these compounds were investigated for their neuroprotective effects against A&#x003b2;-induced toxicity in SH-SY5Y cells. Cell viability, catalase-like activity, ROS levels, mitochondrial function, and cell membrane damage as well as SIRT1 and BACE1 activities were assessed. Furthermore, computational studies, (i.e., molecular docking, assessment of pharmacokinetics, and target prediction) were performed to uncover possible binding modes, drug-likeness of the compounds, and potential biological targets.</p></sec><sec id="Sec2"><title>Materials and Methods</title><sec id="Sec3"><title>Chemical Reagent and Assay</title><p id="Par6">Analytical grade chemicals and reagents were obtained from well-established and reputable suppliers. Beta-amyloid peptide (1&#x02013;42) (human A&#x003b2;<sub>1&#x02013;</sub><sub>42</sub>, Cat. No. ab120301) was sourced from Abcam (Waltham, Boston, USA). Dulbecco&#x02019;s Modified Eagle Medium (DMEM, Cat. No. 31600-034), fetal bovine serum (FBS, Cat. No. A5256701), 0.25% trypsin-EDTA (Cat. No. 25200072), and penicillin/streptomycin (Cat. No. 15140122) were procured from Gibco BRL (Gaithersburg, MD, USA). Additionally, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Cat. No. M6494) and cell-permeant 2&#x02032;,7&#x02032;-dichlorodihydrofluorescein diacetate (DCFDA, Cat. No. D399) were provided by Molecular Probes (Eugene, Oregon, USA). Furthermore, Sigma-Aldrich (St. Louis, Mo, USA) supplied dimethyl sulfoxide (DMSO, Cat. No. 41639), RSV (Cat. No. R5010), mitochondrial-specific fluorescent dye (rhodamine-123, Cat. No. R8004), lactate dehydrogenase (LDH, Cat. No. MAK066), SIRT1 (Cat. No. CS1040), and BACE1 (Cat. No. CS0010) activity assay kits.</p></sec><sec id="Sec4"><title>Preparation of A&#x003b2;<sub>42</sub> Oligomer and Investigated Compounds</title><p id="Par7">A&#x003b2;<sub>42</sub> was dissolved in sterile water and incubated at 37&#x000a0;&#x000b0;C for 24&#x000a0;h to facilitate oligomerization. After the incubation period, the solution underwent centrifugation at 14,000&#x000a0;g for 10&#x000a0;min at 4&#x000a0;&#x000b0;C to remove undissolved fibrils. The resulting supernatant, enriched with A&#x003b2; oligomers, was meticulously transferred to fresh tubes and stored at 4&#x000a0;&#x000b0;C for subsequent utilization [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>].</p><p id="Par8">ANQs (<bold>1</bold>&#x02013;<bold>18</bold>) were synthesized by nucleophilic substitution or Michael addition of various amines with 1,4-NQs reported by our group [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>]. Investigated compounds (<bold>1</bold>&#x02013;<bold>18</bold>) were individually dissolved in DMSO to generate concentrated stock solutions. These stock solutions were then serially diluted in DMEM supplemented with 10% heat-inactivated FBS and 1% penicillin/streptomycin to achieve the desired working concentrations for the experiment. RSV was employed as a positive control due to its established neuroprotection and SIRT1 activator, as documented in previous literature [<xref ref-type="bibr" rid="CR31">31</xref>].</p></sec><sec id="Sec5"><title>Cell Culture</title><p id="Par9">Human SH-SY5Y neuroblastoma cell line was procured from the American Type Culture Collection (ATCC, VA, USA) and cultivated in 75-cm<sup>2</sup> flasks. The growth medium consisted of DMEM supplemented with 10% heat-inactivated FBS and 1% penicillin/streptomycin. The culture was maintained at a temperature of 37&#x000a0;&#x000b0;C within a humidified incubator containing 5% CO<sub>2</sub>. To ensure optimal growth, the culture medium was replaced every three days.</p><p id="Par10">Cell subculture was initiated to facilitate subsequent expansion or experimentation. The used medium was aspirated, and the flask underwent a rinsing step with phosphate-buffered saline (PBS). Subsequently, 1 mL of a 0.25% trypsin-EDTA solution was introduced, and the flask was subjected to a minute incubation period at 37&#x000a0;&#x000b0;C to facilitate effective cell detachment. A gentle shaking motion was applied to aid in the dissociation process. Following the trypsinization, 2 mL of complete DMEM was introduced to deactivate the trypsin, and the resulting cell suspension was carefully transferred to a centrifuge tube. Centrifugation at 1,000&#x000a0;rpm for 5&#x000a0;min at 20&#x000a0;&#x000b0;C was performed to precipitate the cells, and the supernatant was subsequently removed. Lastly, the cell pellet was resuspended in fresh complete DMEM and plated into new culture flasks to perpetuate their growth.</p></sec><sec id="Sec6"><title>Determination of Cell Viability</title><p id="Par11">The SH-SY5Y neuroblastoma cell line was employed as an experimental model. The cells were initially seeded at a density of 1.0&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells/mL in 96-well plates for initial adherence. Treatment regimens differed amongst groups including (i) the control group remained unexposed to ANQs (<bold>1</bold>&#x02013;<bold>18</bold>) or A&#x003b2;<sub>42</sub>, (ii) the toxin-induced group was exposed to 1 &#x000b5;M A&#x003b2;<sub>42</sub>, (iii) the compound-treated group received treatment with ANQs (1&#x02013;18) at concentrations ranging from 0.1 to 100 &#x000b5;M for 24 h, (IV) the compound-pretreated group received pretreatment with ANQs (<bold>1</bold>&#x02013;<bold>18</bold>) at concentrations ranging from 0.1 to 100 &#x000b5;M for 3&#x000a0;h, followed by media refreshment and exposure to 1 &#x000b5;M A&#x003b2;<sub>42</sub> for an additional 24&#x000a0;h. Following the incubation period, 5&#x000a0;mg/mL MTT solution was introduced, and the cells were incubated in darkness at 37&#x000a0;&#x000b0;C for 3&#x000a0;h. Subsequent steps involved media removal, formazan crystal solubilization with 0.04&#x000a0;N HCl in isopropanol, and final absorbance measurement at 570&#x000a0;nm using a microplate reader (Multiskan SkyHigh, Thermo Fisher Scientific, USA). Cell viability was subsequently quantified as a percentage relative to the untreated control group [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec><sec id="Sec7"><title>Evaluation of Cell Morphology</title><p id="Par12">After the overnight culture at a density of 1.0&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells/mL on Petri dishes, the SH-SY5Y cells underwent each specified treatment regimen. Subsequently, cell morphology was examined using an inverted light microscope (Olympus Corporation, Tokyo, Japan) at a 20x magnification with multiple fields. Comprehensive images of both treated and untreated cells were captured for subsequent investigation.</p></sec><sec id="Sec8"><title>Assessment of Catalase-Like Activity</title><p id="Par13">The catalase-like activity was assessed by monitoring the reduction in hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) concentration using a modified method derived from the literature of Rasheed RT, 2020 [<xref ref-type="bibr" rid="CR33">33</xref>], Costa RO, 2018 [<xref ref-type="bibr" rid="CR34">34</xref>], and Goldblith SA, 1950 [<xref ref-type="bibr" rid="CR35">35</xref>]. In brief, either compounds at a concentration of 1 &#x000b5;M or cell lysate after treatment regimen were incubated with 590 mM H<sub>2</sub>O<sub>2</sub> in 0.05&#x000a0;M PBS at pH 7.0 for 30&#x000a0;min. At the end of the incubation, potassium permanganate (KMnO<sub>4</sub>) and sulfuric acid were introduced to the reaction mixture. The purple color of the KMnO<sub>4</sub> solution, reacting with the residual H<sub>2</sub>O<sub>2</sub>, was transformed into a colorless manganese sulfate (MnSO<sub>4</sub>) product. The absorbance was immediately kinetically measured at a wavelength of 525&#x000a0;nm over 30 min. The average rate of absorbance change throughout the reaction time was utilized to quantify the concentration of H<sub>2</sub>O<sub>2</sub>. The results were subsequently expressed as a percentage of H<sub>2</sub>O<sub>2</sub> reductance relative to the control group.</p></sec><sec id="Sec9"><title>Determination of Intracellular ROS</title><p id="Par14">The generation of intracellular ROS was evaluated using the DCFDA fluorescent probe, which detects ROS-mediated oxidation and produces green fluorescence. SH-SY5Y cells were initially plated in 96-well plates at a concentration of 1.0&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells/mL and subjected to the treatment protocol. Following the completion of the treatment regimen, 10 &#x000b5;M DCFDA was introduced and subsequently incubated at 37&#x000a0;&#x000b0;C for 30&#x000a0;min in darkness. The fluorescence intensity was measured using a microplate reader at excitation/emission wavelengths of 495/527 nm. Intracellular ROS production was then expressed as a percentage relative to the control group [<xref ref-type="bibr" rid="CR36">36</xref>].</p></sec><sec id="Sec10"><title>Evaluation of MMP</title><p id="Par15">MMP was assessed using the rhodamine-123 fluorescent probe. SH-SY5Y cells were seeded in 96-well plates at a concentration of 1.0&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells/mL and subjected to the designated treatment regimen. Following the treatment, cells were incubated with 10 &#x000b5;M rhodamine-123 for 30&#x000a0;min in the dark at 37&#x000a0;&#x000b0;C. Fluorescence intensity (488/525 nm excitation/emission) was measured to assess the MMP and expressed as a percentage of the control group [<xref ref-type="bibr" rid="CR37">37</xref>].</p></sec><sec id="Sec11"><title>Assessment of Cellular Membrane Damage</title><p id="Par16">Following respective treatments, supernatant was collected and the LDH activity assay was performed using a commercially available kit according to the manufacturer&#x02019;s instructions. Briefly, the assay measures the conversion of lactate to pyruvate by LDH, leading to NADH production and increased absorbance at 450&#x000a0;nm. The LDH activity was then expressed as a percentage relative to the control group.</p></sec><sec id="Sec12"><title>Measurement of BACE1 Cleavage Activity</title><p id="Par17">The assessment of BACE1 cleavage activity was conducted utilizing the fluorescent BACE1 activity detection kit, following the manufacturer&#x02019;s guidelines. SH-SY5Y cells were seeded in 6-well plates at a density of 1.0&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells/mL and allowed to adhere overnight. Subsequently, the cells were subjected to the designated treatments. Following the treatment, cell lysis was carried out in radioimmunoprecipitation assay buffer (RIPA buffer) supplemented with protease inhibitors at 4&#x000a0;&#x000b0;C for 20&#x000a0;min. Protein concentration was then determined using the Bradford assay. Subsequently, the total protein content for each group was assessed using the BACE1 activity assay, and the resulting fluorescent signals were measured using a microplate reader set to an excitation wavelength of 320&#x000a0;nm and an emission wavelength of 405&#x000a0;nm. BACE1 activity was subsequently expressed as a percentage relative to the control group.</p></sec><sec id="Sec13"><title>Evaluation of SIRT1 Deacetylase Activity</title><p id="Par18">The deacetylase activity of SIRT1 was assessed using the SIRT1 assay kit, according to the manufacturer&#x02019;s instructions. SH-SY5Y cells were seeded in 6-well plates at 1.0&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells/mL and allowed to adhere overnight. Subsequently, the cells underwent the designated treatments. Cells were lysed in cold PBS supplemented with protease inhibitors at 4&#x000a0;&#x000b0;C for 20&#x000a0;min following post-treatment. Then, protein concentration determination was executed for each cell group using the Bradford assay. Finally, the total amount of protein from each group was determined through the SIRT1 assay, and the resulting fluorescent signals were detected using a microplate reader with excitation and emission wavelengths set at 340 and 445&#x000a0;nm, respectively. SIRT1 activity was then expressed as a percentage relative to the control group.</p></sec><sec id="Sec14"><title>Molecular Docking Analysis</title><p id="Par19">Possible binding modes of ANQs against the SIRT1 were simulated using AutoDockTools v.4.2.6 [<xref ref-type="bibr" rid="CR38">38</xref>]. The crystal structure of human SIRT1, in complex with three RSV molecules and an AMC-containing peptide, was retrieved from the Protein Data Bank (PDB code: 5BTR) at 3.2 &#x000c5; resolution [<xref ref-type="bibr" rid="CR39">39</xref>]. Initially, co-crystallized ligands were excluded, and only chain A was selected for further preparation by adding polar hydrogens and charges. Docking parameters were set to be a grid spacing of 0.375 &#x000c5; and a grid box size of 50&#x02009;&#x000d7;&#x02009;50&#x02009;&#x000d7;&#x02009;50 points. The grid box center was positioned at -23.315, 65.890, and 14.723 to encompass the entire activator-binding site between the C-terminal and N-terminal domains of SIRT1. Rotational bonds were defined as rigid for the protein, but flexible for the investigated compounds. Each docking simulation involved 100 independent runs with the Lamarckian Genetic Algorithm as the search strategy and a medium maximum energy level [<xref ref-type="bibr" rid="CR40">40</xref>]. The accuracy of the docking simulations was confirmed by calculating the root-mean-square deviation (RMSD) between the co-crystallized and re-docked RSV molecules. Binding interactions and key residues were visualized and analyzed using Discovery Studio Visualizer 2016 (BIOVIA, Dassault Syst&#x000e8;mes, USA).</p></sec><sec id="Sec15"><title>In Silico Assessment of Pharmacokinetics and Drug-Like Properties</title><p id="Par20">To evaluate the drug-likeness and potential toxicities of the investigated compounds, chemical structures in SMILES format were employed for the prediction using the web server tools, including SwissADME (<ext-link ext-link-type="uri" xlink:href="http://www.swissadme.ch/">http://www.swissadme.ch/</ext-link>) [<xref ref-type="bibr" rid="CR41">41</xref>], pkCSM (<ext-link ext-link-type="uri" xlink:href="http://biosig.unimelb.edu.au/pkcsm/">http://biosig.unimelb.edu.au/pkcsm/</ext-link>) [<xref ref-type="bibr" rid="CR42">42</xref>], and ProTox-II (<ext-link ext-link-type="uri" xlink:href="http://tox-new.charite.de/protox_II/">http://tox-new.charite.de/protox_II/</ext-link>) [<xref ref-type="bibr" rid="CR43">43</xref>]. Then, the data received from all web servers were analyzed.</p></sec><sec id="Sec16"><title>Target Prediction</title><p id="Par21">For the prediction of AD-related gene targets pertaining to our investigated compounds, AD-related genes were sourced from two prominent databases, including DisGeNET [<xref ref-type="bibr" rid="CR44">44</xref>] with a score cutoff of 0.2 and GeneCards [<xref ref-type="bibr" rid="CR45">45</xref>] with a score threshold of 2.57, calculated through median determination. Subsequently, the possible protein targets of the investigated compounds were predicted using two well-established web-based servers including SuperPred [<xref ref-type="bibr" rid="CR46">46</xref>] and SwissTargetPrediction [<xref ref-type="bibr" rid="CR47">47</xref>]. Stringent criteria were set, requiring a minimum cutoff of possibility exceeding 60% and accuracy surpassing 75% for SuperPred. Additionally, proteins with a probability of 0 were eliminated from SwissTargetPrediction, ensuring the reliability of the predictions. The shared common targets were visualized as an intersected area using the VENNY 2.1 online tool (<ext-link ext-link-type="uri" xlink:href="https://bioinfogp.cnb.csic.es/tools/venny/">https://bioinfogp.cnb.csic.es/tools/venny/</ext-link><italic>)</italic> to identify a refined set of potential AD-associated targets specifically interacting with our compounds. This intersection represents a focused list of the target proteins with a high likelihood of being involved in AD as well as a high potential to interact with the studied compounds.</p><p id="Par22">To further investigate the network of interactions and identify key players, the STRING database [<xref ref-type="bibr" rid="CR48">48</xref>] and Cytoscape software [<xref ref-type="bibr" rid="CR49">49</xref>] were utilized for visualization. A protein-protein interaction network was constructed with a high confidence level set at 0.9 and analyzed within Cytoscape software. Proteins with a degree of zero (no connections) were excluded. The prediction focused on only well-connected nodes within the network. Then, the nodes were ranked based on three measures (i.e., degree, closeness centrality, and betweenness centrality) to prioritize the most influential proteins within the network. These metrics capture the direct connections, information flow, and bridging potential of each protein.</p></sec><sec id="Sec17"><title>Statistical Analysis</title><p id="Par23">Statistical analyses were performed using GraphPad Prism 6 (GraphPad Software Inc., CA, USA). One-way analysis of variance (ANOVA) was utilized for statistical comparisons between groups, followed by a Tukey&#x02013;Kramer post-hoc test. The results are expressed as mean&#x02009;&#x000b1;&#x02009;standard error of the mean (SEM) derived from three or more independent experiments. A probability (<italic>P</italic>) value less than 0.05 was considered statistically significant. All raw data are provided in the supplementary file.</p></sec></sec><sec id="Sec18"><title>Results</title><sec id="Sec19"><title>Synthesis of ANQs (1&#x02013;18)</title><p id="Par24">The chemical structures of 18 ANQ derivatives (<bold>1&#x02013;18</bold>, Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>) were previously reported by our group [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>] including series I (<bold>1</bold>&#x02013;<bold>6</bold>, <bold>8</bold>&#x02013;<bold>13</bold>, <bold>16</bold>), series II (<bold>7</bold>, <bold>15</bold>, <bold>17</bold>), and series III (<bold>14</bold>, <bold>18</bold>). These compounds possess a 1,4-NQ core structure with 2-amino or 2-amino-3-halo substituents, in which the 2-amino was substituted by phenyl ring bearing R (electron withdrawing/electron donating groups) substituents on 3- or 4-position.</p><p id="Par25">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Chemical structures of ANQ derivatives (<bold>1&#x02013;18</bold>)</p></caption><graphic xlink:href="11064_2024_4281_Fig1_HTML" id="d33e661"/></fig>
</p></sec><sec id="Sec20"><title>ANQs Enhance Cell Viability Against A&#x003b2;<sub>42</sub>-Treated Cells</title><p id="Par26">The effect of ANQ derivatives on SH-SY5Y neuroblastoma cell viability was evaluated using the MTT assay. SH-SY5Y cells were pretreated with various concentrations of compounds (0.1&#x02013;100 &#x000b5;M) for 24&#x000a0;h in the absence of A&#x003b2;<sub>42</sub>. The results indicated that all compounds exhibited no significant effect on cell viability at minimal doses (0.1&#x02013;1 &#x000b5;M). However, some compounds demonstrated toxicity to the cells at higher concentrations (5&#x02013;100 &#x000b5;M). To represent the AD model, the toxicity of 1 &#x000b5;M A&#x003b2;<sub>42</sub> alone on SH-SY5Y cells was investigated and revealed a notable 25% reduction in cell viability upon the treatment (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A).</p><p id="Par27">The neuroprotective potential of ANQ derivatives was explored by pretreating the SH-SY5Y cells with each compound for 3&#x000a0;h before exposure to 1 &#x000b5;M A&#x003b2;<sub>42</sub> for an additional 24&#x000a0;h. Results demonstrated that 1 &#x000b5;M compounds significantly enhanced cell viability of the pretreated cells, specifically compound <bold>10</bold> (93.38&#x02009;&#x000b1;&#x02009;1.69%), compound <bold>12</bold> (88.66&#x02009;&#x000b1;&#x02009;1.54%), compound <bold>16</bold> (87.38&#x02009;&#x000b1;&#x02009;2.32%), and compound <bold>18</bold> (88.80&#x02009;&#x000b1;&#x02009;2.12%), compared to the cells treated with A&#x003b2;<sub>42</sub> alone (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A). Notably, these compounds elicited protective effects comparable to that of the RSV, a reference compound known for its cell viability protection (87.20&#x02009;&#x000b1;&#x02009;1.13%). Based on the results, these four ANQs (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) at a concentration of 1 &#x000b5;M were selected for further explorations to elucidate potential neuroprotective mechanisms.</p><p id="Par28">
<fig id="Fig2"><label>Fig. 2</label><caption><p>Effects of 18 ANQ derivatives on SH-SY5Y neuroblastoma cell viability and morphology. (<bold>A</bold>) Cell viability was represented as a percentage relative to the control group. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 compared to the control; #<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 compared to the A&#x003b2;<sub>42</sub>. (<bold>B</bold>) Morphological alterations of SH-SY5Y cells were observed under the inverted light microscope at &#x000d7;20 magnification. Scale bar =&#x02009;200&#x000a0;&#x003bc;m</p></caption><graphic xlink:href="11064_2024_4281_Fig2_HTML" id="d33e734"/></fig>
</p></sec><sec id="Sec21"><title>ANQs Did Not Alter Cellular Morphology</title><p id="Par29">Bright-field microscopy revealed the protective effects of the selected compounds (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) against A&#x003b2;<sub>42</sub>-induced neurotoxicity in SH-SY5Y cells. Exposure to A&#x003b2;<sub>42</sub> alone caused notable morphological changes, including cell shrinkage, detachment, and rounding (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B). However, pretreatment with any of the selected ANQs or RSV at 1 &#x000b5;M for 3&#x000a0;h significantly mitigated these A&#x003b2;<sub>42</sub>-induced alterations. The pretreated cells displayed minimized damage, improved adherence, and normal growth patterns compared to the A&#x003b2;<sub>42</sub>-exposed group (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B). These findings suggested that the selected ANQs hold the potential for protecting the neuronal morphology against A&#x003b2;<sub>42</sub>-induced neurotoxicity.</p></sec><sec id="Sec22"><title>Catalase-Like Activity Increased by ANQs Pretreatment</title><p id="Par30">The antioxidant potential of the selected ANQs (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) at 1 &#x000b5;M was evaluated based on their abilities to quench H<sub>2</sub>O<sub>2</sub>. A redox reaction between KMnO<sub>4</sub> and H<sub>2</sub>O<sub>2</sub>, resulting in its decolorization, was employed to monitor the H<sub>2</sub>O<sub>2</sub> levels. Particularly, the co-incubation of H<sub>2</sub>O<sub>2</sub> with these compounds significantly decreased the reduction rate of KMnO<sub>4</sub> by 70% compared to that of the H<sub>2</sub>O<sub>2</sub> alone (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>A).</p><p id="Par31">Furthermore, the antioxidant effect of these compounds on the induction of catalase-like activity was investigated in cell lysates following the designated treatments. Interestingly, pretreatment with the tested compounds significantly increased catalase-like activity compared to the cells solely exposed to 1 &#x000b5;M A&#x003b2;<sub>42</sub> for 24&#x000a0;h, as observed in the decreased H<sub>2</sub>O<sub>2</sub> concentration after incubating with the cell lysate (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B). This suggested that the ANQs might enhance the intrinsic antioxidant defense mechanisms of the cells.</p><p id="Par32">
<fig id="Fig3"><label>Fig. 3</label><caption><p>Effects of selected ANQs (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) on catalase-like activity. (<bold>A</bold>) Percentage of H<sub>2</sub>O<sub>2</sub> reductance from selected compounds (1 &#x000b5;M). (<bold>B</bold>) Percentage of H<sub>2</sub>O<sub>2</sub> reductance from post-treatment cell lysate. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 compared to the control cells; #<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 compared to the A&#x003b2;<sub>42</sub> group</p></caption><graphic xlink:href="11064_2024_4281_Fig3_HTML" id="d33e870"/></fig>
</p></sec><sec id="Sec23"><title>ANQs Diminished Intracellular ROS Generation Against A&#x003b2;<sub>42</sub>-Treated Cells</title><p id="Par33">The effect of selected compounds (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) on intracellular ROS generation was evaluated using the DCFDA fluorescent probe. The cells treated with 1 &#x000b5;M A&#x003b2;<sub>42</sub> for 24&#x000a0;h exhibited a notable increase in fluorescence intensity reaching 126.57&#x02009;&#x000b1;&#x02009;4.76% compared to the control (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A). Conversely, pretreatment with 1 &#x000b5;M of compounds <bold>10</bold>, <bold>12</bold>, <bold>16</bold>, <bold>18</bold>, or RSV for 3&#x000a0;h prior to A&#x003b2;<sub>42</sub> exposure significantly reduced ROS accumulation. This was evident by a decrease in DCFDA fluorescence intensity compared to the control group (compounds <bold>10</bold>: 109.70&#x02009;&#x000b1;&#x02009;0.74%, <bold>12</bold>: 109.54&#x02009;&#x000b1;&#x02009;0.95%, <bold>16</bold>: 111.16&#x02009;&#x000b1;&#x02009;0.97%, <bold>18</bold>: 106.87&#x02009;&#x000b1;&#x02009;1.13%, and RSV: 109.22&#x02009;&#x000b1;&#x02009;1.65%). These findings suggested that the selected ANQs (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) potentially decrease intracellular ROS production comparable to that of the RSV against A&#x003b2;<sub>42</sub>-induced pathogenesis in SH-SY5Y cells. While this result provides preliminary evidence for the potential antioxidant activity of the ANQs, further complementary investigations are still required to fully assess the antioxidant potency of the ANQ derivatives.</p></sec><sec id="Sec24"><title>MMP Maintained by ANQs Pretreatment</title><p id="Par34">The protective potential of selected compounds (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) against mitochondrial dysfunction was investigated by assessing the fluorescent signal emitted from the rhodamine-123 dye. It was found that exposure to 1 &#x000b5;M A&#x003b2;<sub>42</sub> for 24&#x000a0;h resulted in a significant reduction in MMP (85.26&#x02009;&#x000b1;&#x02009;0.91% lower than that of the control group, Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>B). Nevertheless, pretreatment with 1 &#x000b5;M of compounds <bold>10</bold>, <bold>12</bold>, <bold>16</bold>, <bold>18</bold>, or RSV significantly preserved the MMP by 95.24&#x02009;&#x000b1;&#x02009;2.32%, 94.05&#x02009;&#x000b1;&#x02009;1.20%, 94.41&#x02009;&#x000b1;&#x02009;1.77%, 93.52&#x02009;&#x000b1;&#x02009;2.01%, and 94.94&#x02009;&#x000b1;&#x02009;1.09%, respectively, compared to the control group. This suggested the remarkable ability of the compounds to safeguard the mitochondrial function from A&#x003b2;<sub>42</sub>-mediated neurotoxicity.</p></sec><sec id="Sec25"><title>ANQs Protected Cell Membrane Damage in A&#x003b2;<sub>42</sub>-Induced LDH Release</title><p id="Par35">The cell membrane damage was assessed by the release of LDH. Exposure to 1 &#x000b5;M A&#x003b2;<sub>42</sub> for 24&#x000a0;h significantly increased the release of LDH to 120.61&#x02009;&#x000b1;&#x02009;3.48% compared to the control cells (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>C). Importantly, pretreatment with 1 &#x000b5;M of tested compounds (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) or RSV significantly counteracted this A&#x003b2;<sub>42</sub>-induced LDH release as observed by the reduction in LDH release to near-control levels (compounds <bold>10</bold>: 106.24&#x02009;&#x000b1;&#x02009;1.66%, <bold>12</bold>: 106.36&#x02009;&#x000b1;&#x02009;1.29%, <bold>16</bold>: 108.44&#x02009;&#x000b1;&#x02009;1.89%, <bold>18</bold>: 106.73&#x02009;&#x000b1;&#x02009;1.62%, and RSV: 103.35&#x02009;&#x000b1;&#x02009;1.95%). The results showed the membrane-protective properties of these ANQs, which could potentially contribute to their neuroprotective abilities.</p><p id="Par36">
<fig id="Fig4"><label>Fig. 4</label><caption><p>Protective effects of selected ANQs (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) at 1 &#x000b5;M against A&#x003b2;<sub>42</sub>-induced pathological alterations in SH-SY5Y cells. (<bold>A</bold>) Intracellular ROS production, (<bold>B</bold>) MMP, and (<bold>C</bold>) LDH activity. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 compared to the control; #<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 compared to the A&#x003b2;<sub>42</sub> treatment</p></caption><graphic xlink:href="11064_2024_4281_Fig4_HTML" id="d33e1055"/></fig>
</p></sec><sec id="Sec26"><title>ANQs Mitigated BACE1 Cleavage Activity in A&#x003b2;<sub>42</sub>-Induced SH-SY5Y Cells</title><p id="Par37">The influence of selected ANQ derivatives (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) on BACE1 activity within SH-SY5Y cells was assessed using the BACE1 activity kit. Upon treatment with 1 &#x000b5;M A&#x003b2;<sub>42</sub> for 24&#x000a0;h, there was a significant increase in intracellular BACE1 activity (138.81&#x02009;&#x000b1;&#x02009;5.71% compared to the control group, Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). However, pretreatment with the selected ANQs (1 &#x000b5;M) for 3&#x000a0;h prior to 1 &#x000b5;M A&#x003b2;<sub>42</sub> exposure resulted in a notable reduction in BACE1 activity (<bold>10</bold>: 103.05&#x02009;&#x000b1;&#x02009;5.22%, <bold>12</bold>: 108.93&#x02009;&#x000b1;&#x02009;8.81%, <bold>16</bold>: 112.53&#x02009;&#x000b1;&#x02009;3.69%, and <bold>18</bold>: 113.95&#x02009;&#x000b1;&#x02009;7.83%) compared to the control group. Interestingly, the compounds showed comparable effects with those observed for RSV, which maintained BACE1 activity at 111.67&#x02009;&#x000b1;&#x02009;8.16%. These findings highlighted the potential of the selected ANQs in mitigating BACE1 activity.</p><p id="Par38">
<fig id="Fig5"><label>Fig. 5</label><caption><p>Effects of selected ANQs (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) at 1 &#x000b5;M on BACE1 activity against A&#x003b2;<sub>42</sub>-induced SH-SY5Y cells. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 compared to the control; #<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 compared to the A&#x003b2;<sub>42</sub> group</p></caption><graphic xlink:href="11064_2024_4281_Fig5_HTML" id="d33e1128"/></fig>
</p></sec><sec id="Sec27"><title>SIRT1 Deacetylase Activity Modulated by ANQs Pretreatment</title><p id="Par39">The influence of the chosen ANQs (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) on SIRT1 activity within SH-SY5Y cells was examined using the SIRT1 activity kit. Treatment with 1 &#x000b5;M A&#x003b2;<sub>42</sub> for 24&#x000a0;h significantly reduced SIRT1 activity to 72.93&#x02009;&#x000b1;&#x02009;1.61% compared to the control group (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). This indicated the potential role of SIRT1 in A&#x003b2;<sub>42</sub>-mediated neurodegeneration. However, pretreatments with ANQs <bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold> (1 &#x000b5;M) for 3&#x000a0;h before A&#x003b2;<sub>42</sub> exposure remarkably preserved SIRT1 activity by 90.34&#x02009;&#x000b1;&#x02009;6.17%, 87.08&#x02009;&#x000b1;&#x02009;1.05%, 87.19&#x02009;&#x000b1;&#x02009;4.56%, and 86.93&#x02009;&#x000b1;&#x02009;1.75%, respectively, in comparison to the control group. The compounds showed similar effects with those observed for RSV, a well-known SIRT1 activator, which exhibited sustained SIRT1 activity up to 88.32&#x02009;&#x000b1;&#x02009;3.23%. These findings underscored the potential of selected ANQs in preserving SIRT1 activity.</p><p id="Par40">
<fig id="Fig6"><label>Fig. 6</label><caption><p>Effects of selected ANQs (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) at 1 &#x000b5;M on SIRT1 activity in A&#x003b2;<sub>42</sub>-induced SH-SY5Y cells. *<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 compared to the control; #<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 compared to the A&#x003b2;<sub>42</sub> group</p></caption><graphic xlink:href="11064_2024_4281_Fig6_HTML" id="d33e1201"/></fig>
</p></sec><sec id="Sec28"><title>Binding Interaction of ANQs in SIRT1</title><p id="Par41">Molecular docking was conducted to elucidate potential binding modes of the selected compounds (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) toward the target protein, SIRT1 (PDB code 5BTR). This protein structure was selected due to its sufficient resolution and the co-crystallized RSV, a well-known SIRT1 activator, which was used as a reference compound for validation of docking protocol to provide reliable details and binding characteristics necessary for accurate molecular docking. To validate the reliability of simulations, redocking of the co-crystalized RSVs was initially performed. The calculated mean binding free energies for the three co-crystallized molecules (RSV1, RSV2, and RSV3) were determined to be &#x02212;&#x02009;7.49, &#x02212;&#x02009;7.51, and &#x02212;&#x02009;7.39&#x000a0;kcal/mol, respectively. The calculated RMSD value below 2.0 was obtained, indicating the preferable accuracy of the docking protocol. Subsequently, the validated protocol was utilized to explore the binding modes of the studied compounds.</p><p id="Par42">Docking simulations of the studied compounds showed that all investigated compounds (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) could suitably bind within the same activator-binding site of SIRT1 in similar manners to those of RSVs, Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>A-C. Notably, the binding free energies of the docked ANQs <bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold> (&#x02212;&#x02009;9.91, &#x02212;&#x02009;10.47, &#x02212;&#x02009;9.49, and &#x02212;&#x02009;9.34&#x000a0;kcal/mol, respectively) were found to be more favorable than those of the RSV cluster molecules. However, docking algorithms often favor larger compounds because they can form more atomic interactions within the binding site, leading to molecular weight bias in the docking scores. Since our compounds are larger than RSV, this bias could result in an overemphasis on their binding affinities. To address this, we evaluated additional factors such as interacted amino acid and type of interactions to ensure that the observed binding affinities are not solely a result of molecular size but reflect interactions between the compounds and SIRT1. Furthermore, the results of SIRT1 activity assay corroborates these findings, confirming the functional significance of these interactions.</p><p id="Par43">To reveal the pivotal binding interactions, two-dimensional ligand-protein interaction diagrams were generated (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>D). Among three RSV molecules, RSV2 served as a reference model due to its lowest binding free energy among others and its close spatial proximity to the studied compounds. It was demonstrated that the binding of RSV2 was primarily governed by the formations of pi-alkyl interactions with residues LEU206, PRO211, and ILE223, along with a hydrogen bond formation with THR209 and ASN226, as well as a pi-sigma interaction with LEU202. The studied compounds were found to share some key interacting amino acid residues with RSV2 (i.e., ILE223 and ASN226). Notably, the NQ core skeleton and the substituted phenyl ring presented in the compounds could mimic the two phenyl rings of the RSV by playing parts in the formations of pi-alkyl and pi-sigma interactions. However, conventional hydrogen bonding with THR209 residue observed in the binding of RSV was not observed in any studied compounds.</p><p id="Par44">
<fig id="Fig7"><label>Fig. 7</label><caption><p>Possible binding modes and ligand-protein interactions of the selected ANQs (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) against the SIRT1 activator-binding site. (<bold>A</bold>) Three-dimensional (3D) representations of the crystal structure of SIRT1 (PDB: 5BTR) bound with RSV and all studied compounds. (<bold>B</bold>) 3D poses of redocking RSV with RMSD of 0.6466 &#x000c5;. (<bold>C</bold>) 3D depictions of SIRT1 binding interactions with RSV and individual compounds within the activator-binding site. (<bold>D</bold>) Two-dimensional (2D) ligand-protein interaction diagrams of RSV and studied compounds. The interacting residues are depicted as colored circles based on the type of interaction</p></caption><graphic xlink:href="11064_2024_4281_Fig7_HTML" id="d33e1288"/></fig>
</p></sec><sec id="Sec29"><title>In Silico Predictions of Pharmacokinetics and Drug-Likeness of ANQs</title><p id="Par45">A comprehensive prediction of pharmacokinetics of the selected compounds (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) was conducted employing three established web-based tools (i.e., SwissADME, pkCSM, and ProTox-II) as provided in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>. The results indicated that all compounds are drug-like molecules, as shown by the criteria of Lipinski&#x02019;s, Veber&#x02019;s, and Ghose&#x02019;s rules. The compounds exhibited favorable water solubility, optimal lipophilicity (log <italic>P</italic>&#x02009;&#x0003c;&#x02009;5), as well as high intestinal absorption (91.92&#x02013;94.58%) for oral administration. Additionally, these compounds provided moderate drug distribution potential (human VDss of 0.15&#x02013;0.23 log L/kg) as well as moderate CNS and BBB permeabilities, which suggested their abilities to reach the target site in the CNS.</p><p id="Par46">For metabolic considerations, all compounds were identified as substrates of CYP3A4, a major cytochrome P450 enzyme responsible for metabolizing over 90% of available drugs. Furthermore, they were predicted as inhibitors of CYP1A2, CYP2C19, or CYP2C9, which implicated an alternative metabolic fate and potential drug-drug interactions. These findings warrant further investigations regarding their metabolic profiles and possible interactions with other medications or substances.</p><p id="Par47">In terms of drug elimination and toxicity predictions, the studied compounds were predicted to exhibit total clearance ranging from &#x02212;&#x02009;0.018 to &#x02212;&#x02009;0.186 log mL/min/kg. All of them, except for compound <bold>12</bold>, were also identified as substrates of the renal OCT2. This issue should be further investigated to reveal their potential pharmacokinetics-related drug-drug interaction potential. Regarding toxicity, all compounds were classified as moderately hazardous with potential for hepatotoxicity, carcinogenicity, immunogenicity, and mutagenicity. These predictions highlighted the need for further in vitro and in vivo studies to comprehensively assess their safety profiles.</p><p id="Par48">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Predictions of physicochemical characteristics, pharmacokinetics, and toxicity profiles of the selected compounds (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>)<sup>a</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Compound</th><th align="left">10</th><th align="left">12</th><th align="left">16</th><th align="left">18</th></tr><tr><th align="left" colspan="5">Physicochemical Properties</th></tr></thead><tbody><tr><td align="left">Formula</td><td align="left">C<sub>16</sub>H<sub>9</sub>ClN<sub>2</sub>O<sub>4</sub></td><td align="left">C<sub>18</sub>H<sub>12</sub>ClNO<sub>3</sub></td><td align="left">C<sub>17</sub>H<sub>12</sub>ClNO<sub>2</sub></td><td align="left">C<sub>17</sub>H<sub>13</sub>NO<sub>3</sub></td></tr><tr><td align="left">Molecular weight (g/mol)</td><td align="left">328.71</td><td align="left">325.75</td><td align="left">297.74</td><td align="left">279.29</td></tr><tr><td align="left">Num. heavy atoms</td><td align="left">23</td><td align="left">23</td><td align="left">21</td><td align="left">21</td></tr><tr><td align="left">Num. arom. heavy atoms</td><td align="left">12</td><td align="left">12</td><td align="left">12</td><td align="left">12</td></tr><tr><td align="left">Fraction Csp3</td><td align="left">0</td><td align="left">0.06</td><td align="left">0.06</td><td align="left">0.06</td></tr><tr><td align="left">Num. rotatable bonds</td><td align="left">3</td><td align="left">3</td><td align="left">2</td><td align="left">3</td></tr><tr><td align="left">Num. H-bond acceptors</td><td align="left">4</td><td align="left">3</td><td align="left">2</td><td align="left">3</td></tr><tr><td align="left">Num. H-bond donors</td><td align="left">1</td><td align="left">1</td><td align="left">1</td><td align="left">1</td></tr><tr><td align="left">Molar refractivity</td><td align="left">86.69</td><td align="left">88.06</td><td align="left">82.83</td><td align="left">79.56</td></tr><tr><td align="left">TPSA&#x000a0;(&#x000c5;&#x000b2;)</td><td align="left">91.99</td><td align="left">63.24</td><td align="left">46.17</td><td align="left">55.40</td></tr><tr><td align="left">Log&#x000a0;Po/w&#x000a0;(iLOGP)</td><td align="left">1.76</td><td align="left">2.13</td><td align="left">2.37</td><td align="left">2.53</td></tr><tr><td align="left">Water solubility</td><td align="left">Moderately soluble</td><td align="left">Moderately soluble</td><td align="left">Moderately soluble</td><td align="left">Soluble</td></tr><tr><td align="left" colspan="5">
<bold>Drug-likeness</bold>
</td></tr><tr><td align="left">Lipinski</td><td align="left">Yes; 0 violation</td><td align="left">Yes; 0 violation</td><td align="left">Yes; 0 violation</td><td align="left">Yes; 0 violation</td></tr><tr><td align="left">Ghose</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">Veber</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left" colspan="5">
<bold>Pharmacokinetics</bold>
</td></tr><tr><td align="left">
<bold>Absorption</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">CaCO<sub>2</sub> permeability</td><td align="left">0.93</td><td align="left">0.99</td><td align="left">1.38</td><td align="left">1.31</td></tr><tr><td align="left">Intestinal absorption</td><td align="left">91.92</td><td align="left">94.58</td><td align="left">93.02</td><td align="left">94.44</td></tr><tr><td align="left">GI absorption</td><td align="left">High</td><td align="left">High</td><td align="left">High</td><td align="left">High</td></tr><tr><td align="left">
<bold>Distribution</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">VDss<sup>b</sup> (human)</td><td align="left">0.15</td><td align="left">0.20</td><td align="left">0.23</td><td align="left">0.15</td></tr><tr><td align="left">Low &#x0003c; -0.15, high&#x02009;&#x0003e;&#x02009;0.45</td><td align="left">Moderate</td><td align="left">Moderate</td><td align="left">Moderate</td><td align="left">Moderate</td></tr><tr><td align="left">BBB<sup>c</sup> permeability</td><td align="left">-0.28</td><td align="left">-0.08</td><td align="left">0.15</td><td align="left">0.05</td></tr><tr><td align="left">Low &#x0003c; -1, high&#x02009;&#x0003e;&#x02009;0.3</td><td align="left">Moderate</td><td align="left">Moderate</td><td align="left">Moderate</td><td align="left">Moderate</td></tr><tr><td align="left">CNS<sup>d</sup> permeability</td><td align="left">-1.96</td><td align="left">-1.88</td><td align="left">-0.81</td><td align="left">-2.01</td></tr><tr><td align="left">Low &#x0003c; -3, high &#x0003e;-2</td><td align="left">Pass</td><td align="left">Pass</td><td align="left">Pass</td><td align="left">Moderate</td></tr><tr><td align="left">
<bold>Metabolism</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">CYP2D6 substrate</td><td align="left">No</td><td align="left">No</td><td align="left">No</td><td align="left">No</td></tr><tr><td align="left">CYP3A4 substrate</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">CYP1A2 inhibitor</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">CYP2C19 inhibitor</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">CYP2C9 inhibitor</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">No</td><td align="left">No</td></tr><tr><td align="left">CYP2D6 inhibitor</td><td align="left">No</td><td align="left">No</td><td align="left">No</td><td align="left">No</td></tr><tr><td align="left">CYP3A4 inhibitor</td><td align="left">No</td><td align="left">No</td><td align="left">No</td><td align="left">No</td></tr><tr><td align="left">
<bold>Elimination</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Total Clearance</td><td align="left">0.13</td><td align="left">-0.02</td><td align="left">-0.01</td><td align="left">0.19</td></tr><tr><td align="left">Renal OCT2<sup>e</sup> substrate</td><td align="left">No</td><td align="left">Yes</td><td align="left">Yes</td><td align="left">Yes</td></tr><tr><td align="left">
<bold>Toxicity</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left">Predicted LD<sub>50</sub><sup>f</sup> (mg/kg)</td><td align="left">2000</td><td align="left">2000</td><td align="left">1260</td><td align="left">2000</td></tr><tr><td align="left">Predicted Toxicity</td><td align="left">Class: 4</td><td align="left">Class: 4</td><td align="left">Class: 4</td><td align="left">Class: 4</td></tr><tr><td align="left">Hepatotoxicity</td><td align="left">Inactive</td><td align="left">Active</td><td align="left">Active</td><td align="left">Active</td></tr><tr><td align="left">Carcinogenicity</td><td align="left">Inactive</td><td align="left">Inactive</td><td align="left">Active</td><td align="left">Active</td></tr><tr><td align="left">Immunotoxicity</td><td align="left">Active</td><td align="left">Active</td><td align="left">Inactive</td><td align="left">Active</td></tr><tr><td align="left">Mutagenicity</td><td align="left">Active</td><td align="left">Active</td><td align="left">Active</td><td align="left">Active</td></tr><tr><td align="left">Cytotoxicity</td><td align="left">Inactive</td><td align="left">Inactive</td><td align="left">Inactive</td><td align="left">Inactive</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>The prediction was performed using SwissADME (<ext-link ext-link-type="uri" xlink:href="http://www.swissadme.ch/">http://www.swissadme.ch/</ext-link>), pkCSM (<ext-link ext-link-type="uri" xlink:href="http://biosig.unimelb.edu.au/pkcsm/">http://biosig.unimelb.edu.au/pkcsm/</ext-link>), and ProTox-II (<ext-link ext-link-type="uri" xlink:href="http://tox-new.charite.de/protox_II">http://tox-new.charite.de/protox_II</ext-link>)</p><p><sup>b</sup>VDss, volume of distribution</p><p><sup>c</sup>BBB, blood&#x02013;brainbarrier</p><p><sup>d</sup>CNS, central nervous system</p><p><sup>e</sup>Renal OCT2, renal organic cation transporter 2</p><p><sup>f</sup>LD<sub>50</sub>, 50% lethal dose</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec30"><title>Target Prediction of ANQs with Neuroprotection</title><p id="Par49">Diverse resources were employed to comprehensively identify potential therapeutic targets of the studied compounds playing roles in AD. A catalog of 1,623 disease-associating genes was collected. A library of 335 potential protein targets for our investigated compounds was identified. Analysis of overlapping targets revealed a set of 152 shared common genes between the AD-related list and the compound&#x02019;s predicted targets, Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>A. This finding indicated that our ANQs could potentially interact with crucial proteins implicated in AD pathogenesis. A protein-protein interaction network was created to further explore the relationships among these identified targets resulting in a set of 108 proteins with high connections (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>B). These proteins were subsequently ranked using centrality measures (i.e., degree, closeness centrality, and betweenness centrality) to identify potential protein hubs within the network. A set of top 20 ranked core target proteins are summarized in Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>. This ranking prioritizes proteins that play key roles in the interaction network. According to our analysis, SRC, STAT, and JUN emerged as the top 3 nodes based on their centrality measures. This suggests that these proteins are highly connected and influential within the network, potentially playing pivotal roles in the underlying biological processes. While our analysis provides a valuable overview of the protein-protein interaction network, it is important to acknowledge its limitations. The completeness of the pathways represented in the network depends on the quality and comprehensiveness of the underlying used databases. Moreover, this is just a prediction and pathway in the network might not be fully represented, since non-targeted proteins were not use to construct the network. This could potentially overlook important interactions and regulatory mechanisms that are critical to understand the complete biological context. Notably, many well-established players in AD are included in this top-ranked list, which supports the potential therapeutic relevance of our findings.</p><p id="Par50">
<fig id="Fig8"><label>Fig. 8</label><caption><p>Target prediction and core target analysis of selected ANQs (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) in AD. (<bold>A</bold>) Venn diagram of the intersection between AD-related genes and predicted targets of compounds. (<bold>B</bold>) Protein-protein interaction network of 108 core targets</p></caption><graphic xlink:href="11064_2024_4281_Fig8_HTML" id="d33e1997"/></fig>
</p><p id="Par51">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>List of top 20 ranked core target proteins<sup>g</sup></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Protein</th><th align="left">Full Name</th><th align="left">Involvement in AD</th><th align="left">Expression Level Change in AD</th><th align="left">Potential Drug Target</th><th align="left">Degree</th><th align="left">Closeness Centrality</th><th align="left">Betweenness Centrality</th></tr></thead><tbody><tr><td align="left">SRC</td><td align="left">Proto-oncogene tyrosine-protein kinase Src</td><td align="left">Essential for the signaling response induced by A&#x003b2; and subsequent elevations in neuroinflammation in AD [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>].</td><td align="left">Increase</td><td align="left">Inhibitor</td><td char="." align="char">28</td><td char="." align="char">0.540</td><td char="." align="char">0.207</td></tr><tr><td align="left">STAT3</td><td align="left">Signal transducer and activator of transcription 3</td><td align="left">Neuroinflammation and impaired neuronal function [<xref ref-type="bibr" rid="CR52">52</xref>].</td><td align="left">Increase</td><td align="left">Inhibitor</td><td char="." align="char">21</td><td char="." align="char">0.517</td><td char="." align="char">0.169</td></tr><tr><td align="left">JUN</td><td align="left">c-Jun</td><td align="left">Impaired neuronal function, tau phosphorylation, and A&#x003b2; production [<xref ref-type="bibr" rid="CR53">53</xref>].</td><td align="left">Increase</td><td align="left">Inhibitor</td><td char="." align="char">20</td><td char="." align="char">0.503</td><td char="." align="char">0.159</td></tr><tr><td align="left">ESR1</td><td align="left">Estrogen receptor 1</td><td align="left">Neuroprotective effects in females [<xref ref-type="bibr" rid="CR54">54</xref>].</td><td align="left">Decrease (females)</td><td align="left">Activator</td><td char="." align="char">20</td><td char="." align="char">0.487</td><td char="." align="char">0.093</td></tr><tr><td align="left">EGFR</td><td align="left">Epidermal growth factor receptor</td><td align="left">Amyloidogenic receptor facilitates the cellular uptake of preformed fibril and promotes the seeding of misfolded proteins [<xref ref-type="bibr" rid="CR55">55</xref>].</td><td align="left">Increase</td><td align="left">Inhibitor</td><td char="." align="char">16</td><td char="." align="char">0.436</td><td char="." align="char">0.026</td></tr><tr><td align="left">PTPN11</td><td align="left">Protein tyrosine phosphatase, non-receptor type 11</td><td align="left">May induce aggregation of A&#x003b2;, ER stress, and apoptosis [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]</td><td align="left">Increase</td><td align="left">Inhibitor</td><td char="." align="char">16</td><td char="." align="char">0.441</td><td char="." align="char">0.021</td></tr><tr><td align="left">PIK3CA</td><td align="left">Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha</td><td align="left">May reduce hyper-phosphorylation of Tau and inhibit apoptosis [<xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR59">59</xref>].</td><td align="left"><p>Decrease</p><p>(Varied)</p></td><td align="left">Activator</td><td char="." align="char">16</td><td char="." align="char">0.419</td><td char="." align="char">0.046</td></tr><tr><td align="left">MAPK3</td><td align="left">Mitogen-activated protein kinase 3 (ERK1)</td><td align="left">Impaired memory and learning, as well as pro-inflammatory activation of microglia [<xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR61">61</xref>].</td><td align="left">Increase</td><td align="left">Inhibitor</td><td char="." align="char">15</td><td char="." align="char">0.472</td><td char="." align="char">0.066</td></tr><tr><td align="left">PLCG2</td><td align="left">Phospholipase C gamma 2</td><td align="left">May contribute to neurodegeneration [<xref ref-type="bibr" rid="CR62">62</xref>, <xref ref-type="bibr" rid="CR63">63</xref>].</td><td align="left">Increase activity</td><td align="left">Inhibitor</td><td char="." align="char">15</td><td char="." align="char">0.417</td><td char="." align="char">0.059</td></tr><tr><td align="left">MAPK1</td><td align="left">Mitogen-activated protein kinase 1 (ERK2)</td><td align="left">May contribute to neurodegeneration, inflammation, and apoptosis [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>].</td><td align="left">Increase activity</td><td align="left">Inhibitor</td><td char="." align="char">15</td><td char="." align="char">0.457</td><td char="." align="char">0.060</td></tr><tr><td align="left">STAT1</td><td align="left">Signal transducer and activator of transcription 1</td><td align="left">Neuroinflammation and impaired neuronal function [<xref ref-type="bibr" rid="CR66">66</xref>].</td><td align="left">Increase</td><td align="left">Inhibitor</td><td char="." align="char">13</td><td char="." align="char">0.455</td><td char="." align="char">0.015</td></tr><tr><td align="left">EP300</td><td align="left">E1A binding protein p300</td><td align="left">Regulates gene expression and&#x000a0;potential role in AD progression [<xref ref-type="bibr" rid="CR67">67</xref>].</td><td align="left">Increase</td><td align="left">Inhibitor</td><td char="." align="char">13</td><td char="." align="char">0.444</td><td char="." align="char">0.098</td></tr><tr><td align="left">JAK2</td><td align="left">Janus kinase 2</td><td align="left">Associated with Tau-induced neurodegeneration [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR68">68</xref>].</td><td align="left">Increase activity</td><td align="left">Inhibitor</td><td char="." align="char">11</td><td char="." align="char">0.399</td><td char="." align="char">0.003</td></tr><tr><td align="left">TNF</td><td align="left">Tumor Necrosis Factor</td><td align="left">Neuroinflammation and neuronal death [<xref ref-type="bibr" rid="CR69">69</xref>].</td><td align="left">Increase</td><td align="left">Inhibitor</td><td char="." align="char">11</td><td char="." align="char">0.466</td><td char="." align="char">0.156</td></tr><tr><td align="left">MAPK8</td><td align="left">Mitogen-activated protein kinase 8 (JNK)</td><td align="left">Associated with Tau-induced neurodegeneration [<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR68">68</xref>].</td><td align="left">Increase activity</td><td align="left">Inhibitor</td><td char="." align="char">11</td><td char="." align="char">0.441</td><td char="." align="char">0.046</td></tr><tr><td align="left">ESR2</td><td align="left">Estrogen receptor 2</td><td align="left">Potential role in AD, less studied than ESR1 [<xref ref-type="bibr" rid="CR70">70</xref>]</td><td align="left">Unknown</td><td align="left">N/A</td><td char="." align="char">10</td><td char="." align="char">0.419</td><td char="." align="char">0.016</td></tr><tr><td align="left">CASP3</td><td align="left">Caspase 3</td><td align="left">Neuronal cell death [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>].</td><td align="left">Increase</td><td align="left">Inhibitor</td><td char="." align="char">10</td><td char="." align="char">0.387</td><td char="." align="char">0.084</td></tr><tr><td align="left">CREBBP</td><td align="left">CREB-binding protein</td><td align="left">Potential role in memory and learning, role in AD is&#x000a0;unclear [<xref ref-type="bibr" rid="CR73">73</xref>].</td><td align="left">Decrease</td><td align="left">Activation</td><td char="." align="char">10</td><td char="." align="char">0.436</td><td char="." align="char">0.045</td></tr><tr><td align="left">HDAC1</td><td align="left">Histone deacetylase 1</td><td align="left">Maintaining genomic integrity [<xref ref-type="bibr" rid="CR74">74</xref>].</td><td align="left">Decrease</td><td align="left">Activation</td><td char="." align="char">9</td><td char="." align="char">0.417</td><td char="." align="char">0.025</td></tr><tr><td align="left">ERBB2</td><td align="left">Erb-B2 receptor tyrosine kinase 2 (HER2)</td><td align="left">Impaired lysosomal degradation results from suppressed autophagic flux [<xref ref-type="bibr" rid="CR75">75</xref>].</td><td align="left">Increase</td><td align="left">Inhibitor</td><td char="." align="char">9</td><td char="." align="char">0.405</td><td char="." align="char">0.002</td></tr></tbody></table><table-wrap-foot><p><sup>g</sup>A high confidence level set at 0.9 and analyzed within Cytoscape software. Proteins with a degree of zero (no connections) were excluded</p></table-wrap-foot></table-wrap>
</p></sec></sec><sec id="Sec31"><title>Discussion</title><p id="Par52">In this study, a series of 18 ANQ derivatives (<bold>1</bold>&#x02013;<bold>18</bold>) was comprehensively investigated for neuroprotective potentials to reveal their multifaceted effects in combating A&#x003b2;<sub>42</sub>-induced cellular damage in SH-SY5Y cells. A&#x003b2;<sub>42</sub> is well-known for its ability to mimic key pathological features of AD (i.e., cellular toxicity and neuroinflammation). This creates a highly relevant model system for investigating the mechanisms underlying the disease and evaluating potential therapeutic interventions [<xref ref-type="bibr" rid="CR76">76</xref>]. Previous studies reported that 1 &#x000b5;M of A&#x003b2;<sub>42</sub> effectively induces AD pathology and diminishes cell viability as much as 70%. Accordingly, A&#x003b2;<sub>42</sub> at 1 &#x000b5;M was selected as the neurotoxic agent to induce the AD studied model using the cell culture without exposure to A&#x003b2;<sub>42</sub> as the control group.</p><p id="Par53">Cell viability indicated that the tested compounds elicited a dose-dependent effect on neuronal cell survival. All compounds are non-cytotoxic at low concentrations (0.1&#x02013;1 &#x000b5;M), but some of them showed toxicity at higher concentrations (5&#x02013;100 &#x000b5;M). Thus, a concentration of 1 &#x000b5;M was selected for further investigations. It was shown that pretreatment with 1 &#x000b5;M of compounds (<bold>1</bold>&#x02013;<bold>18</bold>) enhanced cell viability of the A&#x003b2;<sub>42</sub>-induced cells. However, only four compounds (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) demonstrated promising protective effects comparable to that of the RSV (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A) and were selected for further experiments. The selected compounds (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) effectively protected the cells against A&#x003b2;<sub>42</sub>-induced cellular and membrane damages as shown by preserved normal cellular morphology (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B) as well as reduced LDH release (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>C). These findings suggested the potential of compounds in stabilizing the cell membranes, preventing membrane leakage, and preserving cellular integrity. These effects could contribute to the maintenance of cellular homeostasis and protection against damages triggered by A&#x003b2;<sub>42</sub>. Furthermore, the compounds effectively protected against A&#x003b2;<sub>42</sub>-mediated mitochondrial dysfunction as demonstrated by preserved MMP, a key indicator of mitochondrial health and function (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>B). This protective property suggested that the compounds may prevent energetic deficits and maintain crucial cellular processes required for neuronal survival. The A&#x003b2;<sub>42</sub> is well-known to induce oxidative damage in neurodegeneration. The selected compounds demonstrated abilities to counteract the A&#x003b2;<sub>42</sub>-induced oxidative stress as shown by their potent antioxidant capacities and abilities to diminish intracellular ROS levels (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A). Additionally, these compounds not only directly scavenge the ROS, but also significantly enhance cellular antioxidant defense mechanisms by increasing catalase-like activity (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>B). This dual antioxidant action suggested their promising potentials as disease-modifying neuroprotective agents. In view of chemical structure and activity relationship (SAR) of the compounds, notable differences between active and inactive compounds were observed. The critical influence of R substituents (type and position) on the phenyl ring is highlighted. As observed for compounds <bold>4</bold> and <bold>10</bold>, and compounds <bold>1</bold> and <bold>12</bold>, which have the same electron withdrawing groups but different positions of NO<sub>2</sub> and COCH<sub>3</sub>, respectively. Only compounds <bold>10</bold> and <bold>12</bold> demonstrated neuroprotective effects. This could be due to such property of functional groups at <italic>meta</italic>-position may be required for appropriate interaction with the site of neuroprotective action. These observations emphasize that types and substitution patterns of R substituents can significantly impact biological activity, guiding further structural optimization to enhance neuroprotective properties. However, further studies on SAR are required to gain deeper insights into the precise influence of these modifications. Moreover, this study was performed in SH-SY5Y cells. Even though they exhibit various neuronal features, they do not fully replicate the complexity of in vivo neuronal environments, such as the influence of glial cells and the extracellular matrix. Hence, the response of SH-SY5Y cells to A&#x003b2; may differ from primary neurons and potentially affect the generalizability of our findings.</p><p id="Par54">In-depth neuroprotective mechanisms of these compounds were demonstrated by their modulating effects on BACE1 and SIRT1 activities. BACE1 enzyme cleaves the amyloid precursor protein and plays an essential role in the production of pathogenic A&#x003b2; [<xref ref-type="bibr" rid="CR2">2</xref>]. BACE1 activity is normally found to increase in AD conditions, however, pretreatment with the selected compounds (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) showed an effective decrease of BACE1 activity in the A&#x003b2;<sub>42</sub>-induced cells (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>). SIRT1 is well-known to play roles in neuroprotection <italic>via</italic> modulating several key neurodegeneration-related pathways such as decreasing the generation and aggregation of misfolded proteins (A&#x003b2;) and inhibiting the transcription of the BACE1 gene, resulting in a decline in BACE1 activity [<xref ref-type="bibr" rid="CR77">77</xref>]. SIRT1 combats oxidative stress, neuroinflammation, and excitotoxicity through upregulating antioxidant proteins including FOXO3a, SOD2, and CAT [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR79">79</xref>]. SIRT1 also promotes cellular health by activating autophagy, a process crucial for clearing damaged proteins and organelles, <italic>via</italic> modulating involved pathways (i.e., AMPK, HIF-1&#x003b1;, and PGC1&#x003b1;) [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>]. Furthermore, SIRT1 plays multifaceted roles in neuronal health (i.e., cellular metabolism, energy homeostasis, and cell membrane repair). Accordingly, activation of SIRT1 is actively pursued as a promising therapeutic strategy for managing neurodegenerative diseases [<xref ref-type="bibr" rid="CR82">82</xref>]. Herein, it was demonstrated that cellular SIRT1 activity was decreased upon induction by A&#x003b2;<sub>42</sub>. Particularly, the selected compounds (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) promisingly preserved SIRT1 activity with comparable potency to that of the RSV, the known SIRT1 activator (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). This was supported by a molecular docking study which indicated that these compounds could suitably bind within the activator-binding site of the SIRT1 target in a similar manner with RSV as demonstrated by shared key interacting amino acid residues (i.e., ILE223 and ASN226). The bindings of these compounds were dominated by pi-interactions formed between the NQ core or substituted phenyl ring of the compounds and SIRT1. Additionally, these compounds showed superior binding affinity towards the SIRT1 as indicated by their lower binding free energy values (compounds from &#x02212;&#x02009;10.47 to &#x02212;&#x02009;9.34&#x000a0;kcal/mol and RSV &#x02212;&#x02009;7.51&#x000a0;kcal/mol) (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>A-D).</p><p id="Par55">In recent years, AD has been recognized as the complexity of pathological processes including A&#x003b2; accumulation, tau hyperphosphorylation, neuroinflammation, and oxidative stress. Traditional drug discovery approaches have often focused on single-target therapies, which may not adequately address the multifaceted nature of the AD. With this context, multi-target drugs offer a promising strategy by simultaneously modulating several biological pathways, potentially leading to more effective therapeutic outcomes [<xref ref-type="bibr" rid="CR83">83</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. This multi-target approach may enhance the efficacy of the ANQ derivatives in mitigating the progression of AD by addressing the disease from multiple angles. Therefore, in silico analysis was used to predict various potential targets associated with our investigated compounds, aiming to identify broader neuroprotective mechanisms, which were highlighted in a list of the top 20 potential AD-associated target proteins (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). These targets play roles in neuroinflammation, neuronal cell death, neuronal functions, and the aggregation of misfolded proteins. Our network analysis unveiled a significant interconnectedness of the proteins within the network (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>B), which suggested that targeting these central hubs could have a cascading effect influencing multiple AD-related pathways. Accordingly, investigated compounds may be able to modulate the A&#x003b2;-induced neuroinflammatory response by targeting Src family kinases [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Moreover, TNF is noteworthy for further investigation regarding the role of neuroinflammation in neurodegeneration [<xref ref-type="bibr" rid="CR69">69</xref>]. Similarly, the JAK/STAT pathway plays a role in chronic neuroinflammation [<xref ref-type="bibr" rid="CR85">85</xref>, <xref ref-type="bibr" rid="CR86">86</xref>]. This suggested that our compounds could be further developed for modulating pro-inflammatory cascades to combat neuroinflammation. Targeting estrogen signaling pathways has shown promise in AD research, particularly for female patients. ESR1 could be a promising target for personalized therapeutics [<xref ref-type="bibr" rid="CR54">54</xref>]. Several targets relating the neuronal death were identified. Caspase 3 is a central player in neuronal apoptosis [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. Several identified proteins also intimately link to the MAPK pathway, which is implicated in neuronal cell death and AD progression [<xref ref-type="bibr" rid="CR87">87</xref>, <xref ref-type="bibr" rid="CR88">88</xref>]. Lastly, the identified proteins influence the FOXO pathway (i.e., PI3K, JNK, MAPK, CREBBP, STAT, and EGFR), which suggests the protective possibilities against the devastating effects of this hallmark protein [<xref ref-type="bibr" rid="CR86">86</xref>]. Interestingly, both MAPK and FOXO pathways are known to be regulated by SIRT1 activity [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR89">89</xref>, <xref ref-type="bibr" rid="CR90">90</xref>]. This finding together with our in vitro results potentially suggested a unifying mechanism underlying the neuroprotective effects of the studied ANQs through the downstream targets of SIRT1. Taken together, the findings highlighted that the ANQs are promising compounds to be further developed as multifunctional neuroprotective agents to combat the multifaceted pathogenesis of AD. However, future studies regarding experimental target validation and functional studies to elucidate their impacts on relevant AD-related cellular processes are highly recommended.</p><p id="Par56">Preferable pharmacokinetics and toxicity profiles are essential for successful drug development. In silico predictions demonstrated that all four compounds (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) are drug-like compounds with favorable pharmacokinetics for potential oral administration (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Their moderate CNS and BBB permeabilities indicated their access to the target site in the CNS. However, all compounds are CYP3A4 substrates and some of them are inhibitors of other CYPs. This raised the concerning issue regarding their drug-drug or food-drug interaction potentials and further investigations are recommended. Although these compounds were predicted as moderately hazardous, it is suggested that in vitro and in vivo studies on hepatotoxicity, carcinogenicity, and other toxic issues should be further investigated.</p></sec><sec id="Sec32"><title>Conclusion</title><p id="Par57">A series of 18 ANQ derivatives were comprehensively investigated for their neuroprotective potentials against AD in the A&#x003b2;<sub>42</sub>-induced SH-SY5Y cells. Among all tested compounds, four compounds (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) at 1 &#x000b5;M were selected for further experiments due to their promising protective effects comparable to that of the RSV (84.61%). The structural features of these compounds are NQs with 2-aminophenyl containing R substituents (3-NO<sub>2</sub>, 3-COCH<sub>3</sub>, and 4-CH<sub>3</sub>)-3-chloro groups as noted for compounds <bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <italic>R</italic>&#x02009;=&#x02009;4-OCH<sub>3</sub> for compound <bold>18</bold>. The mechanisms underlying this protection were revealed <italic>via</italic> their abilities against intracellular ROS production and cellular membrane damage as well as maintaining mitochondrial function. Furthermore, the compounds effectively modulated BACE1 and SIRT1 activities, which highlighted the potential for the reduction of A&#x003b2;<sub>42</sub> accumulation and other key harmful events. This was supported by the molecular docking study, which showed that these compounds (<bold>10</bold>, <bold>12</bold>, <bold>16</bold>, and <bold>18</bold>) are potential SIRT1 activators. The NQ core and the terminal substituted phenyl ring presented in the molecules were noted to be essential key structural features required for interactions with key interacting amino acid residues (i.e., ILE223 and ASN226). Target prediction indicated a top-ranked list of possible AD-related targets of these compounds, which demonstrated their potentials for combating the complexing of the disease in multiple facets (i.e., neuroinflammation, neuronal cell death, and misfolded proteins) under the SIRT1 regulation. Additionally, predictions of pharmacokinetics and toxicity profiles suggested that these compounds are drug-like molecules with CNS-penetrating ability as well as good intestinal absorption. Taken together, these ANQ compounds are promising candidates for further development as oral disease-modifying agents for the management of AD.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This work was supported by the Srinakharinwirot University and National Science, Research and Innovation Fund (NSRF) (grant no. 029/2566) and Mahidol University (Fundamental Fund; fiscal year 2023 by National Science Research and Innovation Fund (NSRF)).</p></ack><notes notes-type="author-contribution"><title>Author Contributions</title><p>Setthawut Apiraksattayakul: Investigation, Formal analysis, Writing-Original draft preparation; Ratchanok Pingaew: Conceptualization, Methodology, Resources, Funding acquisition, Writing- Reviewing and Editing, Supervision; Veda Prachayasittikul: Formal analysis, Funding acquisition, Writing- Reviewing and Editing; Waralee Ruankham: Methodology, Writing- Reviewing and Editing; Tanawut Tantimongcolwat: Conceptualization, Methodology, Writing- Reviewing and Editing; Virapong Prachayasittikul: Conceptualization, Funding acquisition, Writing-Reviewing and Editing; Supaluk Prachayasittikul: Conceptualization, Methodology, Resources, Funding acquisition, Writing-Reviewing and Editing, Kamonrat Phopin: Conceptualization, Methodology, Formal analysis, Resources, Funding acquisition, Writing- Reviewing and Editing, Supervision.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by Mahidol University</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>The data and materials that support the findings of this study are available from the corresponding author upon reasonable request.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing Interests</title><p id="Par58">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Scheltens</surname><given-names>P</given-names></name><etal/></person-group><source>Alzheimer&#x02019;s Disease Lancet</source><year>2021</year><volume>397</volume><issue>10284</issue><fpage>1577</fpage><lpage>1590</lpage><pub-id pub-id-type="pmid">33667416</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Scheltens P et al (2021) Alzheimer&#x02019;s disease Lancet 397(10284):1577&#x02013;1590<pub-id pub-id-type="pmid">33667416</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>L</given-names></name><etal/></person-group><article-title>New insights into the pathogenesis of Alzheimer&#x02019;s Disease</article-title><source>Front Neurol</source><year>2019</year><volume>10</volume><fpage>1312</fpage><pub-id pub-id-type="pmid">31998208</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Fan L et al (2019) New insights into the pathogenesis of Alzheimer&#x02019;s disease. Front Neurol 10:1312<pub-id pub-id-type="pmid">31998208</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Tamagno</surname><given-names>E</given-names></name><etal/></person-group><article-title>Oxidative stress and Beta amyloid in Alzheimer&#x02019;s Disease. Which comes first: the Chicken or the Egg?</article-title><source>Antioxid (Basel)</source><year>2021</year><volume>10</volume><issue>9</issue><fpage>1479</fpage></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Tamagno E et al (2021) Oxidative stress and Beta amyloid in Alzheimer&#x02019;s disease. Which comes first: the Chicken or the Egg? Antioxid (Basel) 10(9):1479</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Zhao Y, Zhao B (2013) Oxidative stress and the pathogenesis of Alzheimer&#x02019;s disease. Oxid Med Cell Longev, 2013: p. 316523</mixed-citation></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Cha</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>BH</given-names></name></person-group><article-title>Crosstalk between neuron and glial cells in oxidative injury and neuroprotection</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><issue>24</issue><fpage>13315</fpage><pub-id pub-id-type="pmid">34948108</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Lee KH, Cha M, Lee BH (2021) Crosstalk between neuron and glial cells in oxidative injury and neuroprotection. Int J Mol Sci 22(24):13315<pub-id pub-id-type="pmid">34948108</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Ulku I et al (2024) Inhibition of BACE1 affected both its A&#x003b2; producing and degrading activities and increased A&#x003b2;42 and A&#x003b2;40 levels at high-level BACE1 expression. J Biol Chem, 300(8)</mixed-citation></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>McDade</surname><given-names>E</given-names></name><etal/></person-group><article-title>The case for low-level BACE1 inhibition for the prevention of Alzheimer disease</article-title><source>Nat Rev Neurol</source><year>2021</year><volume>17</volume><issue>11</issue><fpage>703</fpage><lpage>714</lpage><pub-id pub-id-type="pmid">34548654</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">McDade E et al (2021) The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nat Rev Neurol 17(11):703&#x02013;714<pub-id pub-id-type="pmid">34548654</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Hatami M et al (2023) Antioxidant Compounds in the Treatment of Alzheimer&#x02019;s Disease: Natural, Hybrid, and Synthetic Products. Evid Based Complement Alternat Med, 2023: p. 8056462</mixed-citation></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Pritam</surname><given-names>P</given-names></name><etal/></person-group><article-title>Antioxidants in Alzheimer&#x02019;s Disease: current therapeutic significance and future prospects</article-title><source>Biology (Basel)</source><year>2022</year><volume>11</volume><issue>2</issue><fpage>212</fpage><pub-id pub-id-type="pmid">35205079</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Pritam P et al (2022) Antioxidants in Alzheimer&#x02019;s disease: current therapeutic significance and future prospects. Biology (Basel) 11(2):212<pub-id pub-id-type="pmid">35205079</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Varshini MS et al (2023) Novel therapeutic targets for treating Alzheimer&#x02019;s disease, in deciphering drug targets for Alzheimer&#x02019;s Disease. Springer, pp 19&#x02013;39</mixed-citation></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Campora</surname><given-names>M</given-names></name><etal/></person-group><article-title>Journey on Naphthoquinone and anthraquinone derivatives: New insights in Alzheimer&#x02019;s Disease</article-title><source>Pharmaceuticals (Basel)</source><year>2021</year><volume>14</volume><issue>1</issue><fpage>33</fpage><pub-id pub-id-type="pmid">33466332</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Campora M et al (2021) Journey on Naphthoquinone and anthraquinone derivatives: New insights in Alzheimer&#x02019;s disease. Pharmaceuticals (Basel) 14(1):33<pub-id pub-id-type="pmid">33466332</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Estolano-Cobi&#x000e1;n</surname><given-names>A</given-names></name><etal/></person-group><article-title>Antioxidant, antiproliferative, and acetylcholinesterase inhibition activity of amino alcohol derivatives from 1,4-naphthoquinone</article-title><source>Med Chem Res</source><year>2020</year><volume>29</volume><issue>11</issue><fpage>1986</fpage><lpage>1999</lpage></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Estolano-Cobi&#x000e1;n A et al (2020) Antioxidant, antiproliferative, and acetylcholinesterase inhibition activity of amino alcohol derivatives from 1,4-naphthoquinone. Med Chem Res 29(11):1986&#x02013;1999</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Campora</surname><given-names>M</given-names></name><etal/></person-group><article-title>Multitarget Biological profiling of New Naphthoquinone and Anthraquinone-based derivatives for the treatment of Alzheimer&#x02019;s Disease</article-title><source>ACS Chem Neurosci</source><year>2021</year><volume>12</volume><issue>3</issue><fpage>447</fpage><lpage>461</lpage><pub-id pub-id-type="pmid">33428389</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Campora M et al (2021) Multitarget Biological profiling of New Naphthoquinone and Anthraquinone-based derivatives for the treatment of Alzheimer&#x02019;s Disease. ACS Chem Neurosci 12(3):447&#x02013;461<pub-id pub-id-type="pmid">33428389</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>X</given-names></name><etal/></person-group><article-title>Structural and pharmacological diversity of 1, 4-naphthoquinone glycosides in recent 20 years</article-title><source>Bioorg Chem</source><year>2023</year><volume>138</volume><fpage>106643</fpage><pub-id pub-id-type="pmid">37329815</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Shen X et al (2023) Structural and pharmacological diversity of 1, 4-naphthoquinone glycosides in recent 20 years. Bioorg Chem 138:106643<pub-id pub-id-type="pmid">37329815</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Aminin</surname><given-names>D</given-names></name><name><surname>Polonik</surname><given-names>S</given-names></name></person-group><article-title>1, 4-Naphthoquinones: some biological properties and application</article-title><source>Chem Pharm Bull</source><year>2020</year><volume>68</volume><issue>1</issue><fpage>46</fpage><lpage>57</lpage></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Aminin D, Polonik S (2020) 1, 4-Naphthoquinones: some biological properties and application. Chem Pharm Bull 68(1):46&#x02013;57</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Agafonova</surname><given-names>I</given-names></name><etal/></person-group><article-title>Protection Activity of 1, 4-Naphthoquinones in Rotenone-Induced models of Neurotoxicity</article-title><source>Mar Drugs</source><year>2024</year><volume>22</volume><issue>2</issue><fpage>62</fpage><pub-id pub-id-type="pmid">38393033</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Agafonova I et al (2024) Protection Activity of 1, 4-Naphthoquinones in Rotenone-Induced models of Neurotoxicity. Mar Drugs 22(2):62<pub-id pub-id-type="pmid">38393033</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>DM</given-names></name><etal/></person-group><article-title>Synthetic condensed 1,4-naphthoquinone derivative shifts neural stem cell differentiation by regulating redox state</article-title><source>Mol Neurobiol</source><year>2013</year><volume>47</volume><issue>1</issue><fpage>313</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">23054678</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Santos DM et al (2013) Synthetic condensed 1,4-naphthoquinone derivative shifts neural stem cell differentiation by regulating redox state. Mol Neurobiol 47(1):313&#x02013;324<pub-id pub-id-type="pmid">23054678</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Gong Z et al (2023) Rhinacanthin C Ameliorates Insulin Resistance and Lipid Accumulation in NAFLD Mice via the AMPK/SIRT1 and SREBP-1c/FAS/ACC Signaling Pathways. Evid Based Complement Alternat Med, 2023: p. 6603522</mixed-citation></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Wahedi</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Juglone up-regulates sirt1 in skin cells under normal and UVB irradiated conditions</article-title><source>J Dermatol Sci</source><year>2016</year><volume>81</volume><issue>3</issue><fpage>210</fpage><lpage>212</lpage><pub-id pub-id-type="pmid">26747057</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Wahedi HM et al (2016) Juglone up-regulates sirt1 in skin cells under normal and UVB irradiated conditions. J Dermatol Sci 81(3):210&#x02013;212<pub-id pub-id-type="pmid">26747057</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>SY</given-names></name><name><surname>Tang</surname><given-names>BL</given-names></name></person-group><article-title>SIRT1 as a therapeutic target for Alzheimer&#x02019;s disease</article-title><source>Rev Neurosci</source><year>2016</year><volume>27</volume><issue>8</issue><fpage>813</fpage><lpage>825</lpage><pub-id pub-id-type="pmid">27497424</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Wong SY, Tang BL (2016) SIRT1 as a therapeutic target for Alzheimer&#x02019;s disease. Rev Neurosci 27(8):813&#x02013;825<pub-id pub-id-type="pmid">27497424</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Donmez</surname><given-names>G</given-names></name></person-group><article-title>The effects of SIRT1 on Alzheimer&#x02019;s Disease models</article-title><source>Int J Alzheimers Dis</source><year>2012</year><volume>2012</volume><fpage>509529</fpage><pub-id pub-id-type="pmid">23251824</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Donmez G (2012) The effects of SIRT1 on Alzheimer&#x02019;s disease models. Int J Alzheimers Dis 2012:509529<pub-id pub-id-type="pmid">23251824</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Gomes BAQ et al (2018) Neuroprotective Mechanisms of Resveratrol in Alzheimer&#x02019;s disease: Role of SIRT1. Oxid Med Cell Longev, 2018: p. 8152373</mixed-citation></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Niazi</surname><given-names>SK</given-names></name><name><surname>Mariam</surname><given-names>Z</given-names></name></person-group><article-title>Computer-aided Drug Design and Drug Discovery: a prospective analysis</article-title><source>Pharmaceuticals (Basel)</source><year>2023</year><volume>17</volume><issue>1</issue><fpage>22</fpage><pub-id pub-id-type="pmid">38256856</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Niazi SK, Mariam Z (2023) Computer-aided Drug Design and Drug Discovery: a prospective analysis. Pharmaceuticals (Basel) 17(1):22<pub-id pub-id-type="pmid">38256856</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><etal/></person-group><article-title>In silico methods for identification of potential therapeutic targets</article-title><source>Interdiscip Sci</source><year>2022</year><volume>14</volume><issue>2</issue><fpage>285</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">34826045</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Zhang X et al (2022) In silico methods for identification of potential therapeutic targets. Interdiscip Sci 14(2):285&#x02013;310<pub-id pub-id-type="pmid">34826045</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Adelusi</surname><given-names>TI</given-names></name><etal/></person-group><article-title>Molecular modeling in drug discovery</article-title><source>Inf Med Unlocked</source><year>2022</year><volume>29</volume><fpage>100880</fpage></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Adelusi TI et al (2022) Molecular modeling in drug discovery. Inf Med Unlocked 29:100880</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>DE</given-names></name><name><surname>Pickett</surname><given-names>SD</given-names></name></person-group><article-title>Computational methods for the prediction of &#x02018;drug-likeness&#x02019;</article-title><source>Drug Discov Today</source><year>2000</year><volume>5</volume><issue>2</issue><fpage>49</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">10652455</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Clark DE, Pickett SD (2000) Computational methods for the prediction of &#x02018;drug-likeness&#x02019;. Drug Discov Today 5(2):49&#x02013;58<pub-id pub-id-type="pmid">10652455</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Mahalapbutr</surname><given-names>P</given-names></name><etal/></person-group><article-title>Discovery of Anilino-1,4-naphthoquinones as potent EGFR tyrosine kinase inhibitors: synthesis, Biological evaluation, and Comprehensive Molecular modeling</article-title><source>ACS Omega</source><year>2022</year><volume>7</volume><issue>21</issue><fpage>17881</fpage><lpage>17893</lpage><pub-id pub-id-type="pmid">35664590</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Mahalapbutr P et al (2022) Discovery of Anilino-1,4-naphthoquinones as potent EGFR tyrosine kinase inhibitors: synthesis, biological evaluation, and comprehensive molecular modeling. ACS Omega 7(21):17881&#x02013;17893<pub-id pub-id-type="pmid">35664590</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Prachayasittikul</surname><given-names>V</given-names></name><etal/></person-group><article-title>Synthesis, anticancer activity and QSAR study of 1,4-naphthoquinone derivatives</article-title><source>Eur J Med Chem</source><year>2014</year><volume>84</volume><fpage>247</fpage><lpage>263</lpage><pub-id pub-id-type="pmid">25019480</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Prachayasittikul V et al (2014) Synthesis, anticancer activity and QSAR study of 1,4-naphthoquinone derivatives. Eur J Med Chem 84:247&#x02013;263<pub-id pub-id-type="pmid">25019480</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>LL</given-names></name><etal/></person-group><article-title>Atorvastatin prevents amyloid-beta peptide oligomer-induced synaptotoxicity and memory dysfunction in rats through a p38 MAPK-dependent pathway</article-title><source>Acta Pharmacol Sin</source><year>2014</year><volume>35</volume><issue>6</issue><fpage>716</fpage><lpage>726</lpage><pub-id pub-id-type="pmid">24793311</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Zhang LL et al (2014) Atorvastatin prevents amyloid-beta peptide oligomer-induced synaptotoxicity and memory dysfunction in rats through a p38 MAPK-dependent pathway. Acta Pharmacol Sin 35(6):716&#x02013;726<pub-id pub-id-type="pmid">24793311</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Sooknual</surname><given-names>P</given-names></name><etal/></person-group><article-title>Synthesis and neuroprotective effects of novel chalcone-triazole hybrids</article-title><source>Bioorg Chem</source><year>2020</year><volume>105</volume><fpage>104384</fpage><pub-id pub-id-type="pmid">33130346</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Sooknual P et al (2020) Synthesis and neuroprotective effects of novel chalcone-triazole hybrids. Bioorg Chem 105:104384<pub-id pub-id-type="pmid">33130346</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Borra</surname><given-names>MT</given-names></name><name><surname>Smith</surname><given-names>BC</given-names></name><name><surname>Denu</surname><given-names>JM</given-names></name></person-group><article-title>Mechanism of human SIRT1 activation by resveratrol</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><issue>17</issue><fpage>17187</fpage><lpage>17195</lpage><pub-id pub-id-type="pmid">15749705</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Borra MT, Smith BC, Denu JM (2005) Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 280(17):17187&#x02013;17195<pub-id pub-id-type="pmid">15749705</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Apiraksattayakul</surname><given-names>S</given-names></name><etal/></person-group><article-title>Neuroprotective properties of Bis-Sulfonamide derivatives against 6-OHDA-Induced Parkinson&#x02019;s Model via Sirtuin 1 activity and in silico Pharmacokinetic Properties</article-title><source>Front Mol Neurosci</source><year>2022</year><volume>15</volume><fpage>890838</fpage><pub-id pub-id-type="pmid">35935335</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Apiraksattayakul S et al (2022) Neuroprotective properties of Bis-Sulfonamide derivatives against 6-OHDA-Induced Parkinson&#x02019;s Model via Sirtuin 1 activity and in silico Pharmacokinetic Properties. Front Mol Neurosci 15:890838<pub-id pub-id-type="pmid">35935335</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Rasheed</surname><given-names>RT</given-names></name><name><surname>Mansoor</surname><given-names>HS</given-names></name><name><surname>Mansoor</surname><given-names>AS</given-names></name></person-group><article-title>New colorimetric method to determine catalase mimic activity</article-title><source>Mater Res Express</source><year>2020</year><volume>7</volume><issue>2</issue><fpage>025405</fpage></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Rasheed RT, Mansoor HS, Mansoor AS (2020) New colorimetric method to determine catalase mimic activity. Mater Res Express 7(2):025405</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Costa</surname><given-names>RO</given-names></name><etal/></person-group><article-title>A new mixed-valence mn(II)mn(III) compound with catalase and Superoxide dismutase activities</article-title><source>Front Chem</source><year>2018</year><volume>6</volume><fpage>491</fpage><pub-id pub-id-type="pmid">30456211</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Costa RO et al (2018) A new mixed-valence mn(II)mn(III) compound with catalase and Superoxide dismutase activities. Front Chem 6:491<pub-id pub-id-type="pmid">30456211</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Goldblith</surname><given-names>SA</given-names></name><name><surname>Proctor</surname><given-names>BE</given-names></name></person-group><article-title>Photometric determination of catalase activity</article-title><source>J Biol Chem</source><year>1950</year><volume>187</volume><issue>2</issue><fpage>705</fpage><lpage>709</lpage><pub-id pub-id-type="pmid">14803454</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Goldblith SA, Proctor BE (1950) Photometric determination of catalase activity. J Biol Chem 187(2):705&#x02013;709<pub-id pub-id-type="pmid">14803454</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Apiraksattayakul</surname><given-names>S</given-names></name><etal/></person-group><article-title>Aminochalcones attenuate neuronal cell death under oxidative damage via Sirtuin 1 activity</article-title><source>ACS Omega</source><year>2023</year><volume>8</volume><issue>37</issue><fpage>33367</fpage><lpage>33379</lpage><pub-id pub-id-type="pmid">37744807</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Apiraksattayakul S et al (2023) Aminochalcones attenuate neuronal cell death under oxidative damage via Sirtuin 1 activity. ACS Omega 8(37):33367&#x02013;33379<pub-id pub-id-type="pmid">37744807</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Ferlini</surname><given-names>C</given-names></name><name><surname>Scambia</surname><given-names>G</given-names></name></person-group><article-title>Assay for apoptosis using the mitochondrial probes, Rhodamine123 and 10-N-nonyl acridine orange</article-title><source>Nat Protoc</source><year>2007</year><volume>2</volume><issue>12</issue><fpage>3111</fpage><lpage>3114</lpage><pub-id pub-id-type="pmid">18079710</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Ferlini C, Scambia G (2007) Assay for apoptosis using the mitochondrial probes, Rhodamine123 and 10-N-nonyl acridine orange. Nat Protoc 2(12):3111&#x02013;3114<pub-id pub-id-type="pmid">18079710</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="other">Huey R, Morris GM, Forli S (2012) Using AutoDock 4 and AutoDock Vina with AutoDockTools: a tutorial, vol 10550. The Scripps Research Institute Molecular Graphics Laboratory, p 1000. 92037</mixed-citation></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>D</given-names></name><etal/></person-group><article-title>Structural basis for allosteric, substrate-dependent stimulation of SIRT1 activity by resveratrol</article-title><source>Genes Dev</source><year>2015</year><volume>29</volume><issue>12</issue><fpage>1316</fpage><lpage>1325</lpage><pub-id pub-id-type="pmid">26109052</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Cao D et al (2015) Structural basis for allosteric, substrate-dependent stimulation of SIRT1 activity by resveratrol. Genes Dev 29(12):1316&#x02013;1325<pub-id pub-id-type="pmid">26109052</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function</article-title><source>J Comput Chem</source><year>1998</year><volume>19</volume><issue>14</issue><fpage>1639</fpage><lpage>1662</lpage></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Morris GM et al (1998) Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19(14):1639&#x02013;1662</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Daina</surname><given-names>A</given-names></name><name><surname>Michielin</surname><given-names>O</given-names></name><name><surname>Zoete</surname><given-names>V</given-names></name></person-group><article-title>SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>42717</fpage><pub-id pub-id-type="pmid">28256516</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 7(1):42717<pub-id pub-id-type="pmid">28256516</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Pires</surname><given-names>DE</given-names></name><name><surname>Blundell</surname><given-names>TL</given-names></name><name><surname>Ascher</surname><given-names>DB</given-names></name></person-group><article-title>pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity properties using graph-based signatures</article-title><source>J Med Chem</source><year>2015</year><volume>58</volume><issue>9</issue><fpage>4066</fpage><lpage>4072</lpage><pub-id pub-id-type="pmid">25860834</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Pires DE, Blundell TL, Ascher DB (2015) pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J Med Chem 58(9):4066&#x02013;4072<pub-id pub-id-type="pmid">25860834</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Banerjee</surname><given-names>P</given-names></name><etal/></person-group><article-title>ProTox-II: a webserver for the prediction of toxicity of chemicals</article-title><source>Nucleic Acids Res</source><year>2018</year><volume>46</volume><issue>W1</issue><fpage>W257</fpage><lpage>W263</lpage><pub-id pub-id-type="pmid">29718510</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Banerjee P et al (2018) ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res 46(W1):W257&#x02013;W263<pub-id pub-id-type="pmid">29718510</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Pinero</surname><given-names>J</given-names></name><etal/></person-group><article-title>DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants</article-title><source>Nucleic Acids Res</source><year>2017</year><volume>45</volume><issue>D1</issue><fpage>D833</fpage><lpage>D839</lpage><pub-id pub-id-type="pmid">27924018</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Pinero J et al (2017) DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Res 45(D1):D833&#x02013;D839<pub-id pub-id-type="pmid">27924018</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Stelzer</surname><given-names>G</given-names></name><etal/></person-group><article-title>The GeneCards suite: from Gene Data Mining to Disease Genome sequence analyses</article-title><source>Curr Protoc Bioinf</source><year>2016</year><volume>54</volume><issue>1</issue><fpage>1</fpage></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Stelzer G et al (2016) The GeneCards suite: from Gene Data Mining to disease genome sequence analyses. Curr Protoc Bioinf 54(1):1</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Nickel J et al (2014) SuperPred: update on drug classification and target prediction. Nucleic Acids Res 42(1):W26&#x02013;31</mixed-citation></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Daina</surname><given-names>A</given-names></name><name><surname>Michielin</surname><given-names>O</given-names></name><name><surname>Zoete</surname><given-names>V</given-names></name></person-group><article-title>SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules</article-title><source>Nucleic Acids Res</source><year>2019</year><volume>47</volume><issue>W1</issue><fpage>W357</fpage><lpage>W364</lpage><pub-id pub-id-type="pmid">31106366</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Daina A, Michielin O, Zoete V (2019) SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res 47(W1):W357&#x02013;W364<pub-id pub-id-type="pmid">31106366</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>von Mering</surname><given-names>C</given-names></name><etal/></person-group><article-title>STRING: a database of predicted functional associations between proteins</article-title><source>Nucleic Acids Res</source><year>2003</year><volume>31</volume><issue>1</issue><fpage>258</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">12519996</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">von Mering C et al (2003) STRING: a database of predicted functional associations between proteins. Nucleic Acids Res 31(1):258&#x02013;261<pub-id pub-id-type="pmid">12519996</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Shannon</surname><given-names>P</given-names></name><etal/></person-group><article-title>Cytoscape: a software environment for integrated models of biomolecular interaction networks</article-title><source>Genome Res</source><year>2003</year><volume>13</volume><issue>11</issue><fpage>2498</fpage><lpage>2504</lpage><pub-id pub-id-type="pmid">14597658</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Shannon P et al (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13(11):2498&#x02013;2504<pub-id pub-id-type="pmid">14597658</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="other">Beirute-Herrera JL et al (2020) The implication of SRC family kinases in Alzheimer&#x02019;s disease, vol 16. Alzheimer&#x02019;s &#x00026; Dementia, p e038447. S2</mixed-citation></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Dhawan</surname><given-names>G</given-names></name><name><surname>Combs</surname><given-names>CK</given-names></name></person-group><article-title>Inhibition of src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer&#x02019;s disease</article-title><source>J Neuroinflammation</source><year>2012</year><volume>9</volume><issue>1</issue><fpage>117</fpage><pub-id pub-id-type="pmid">22673542</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Dhawan G, Combs CK (2012) Inhibition of src kinase activity attenuates amyloid associated microgliosis in a murine model of Alzheimer&#x02019;s disease. J Neuroinflammation 9(1):117<pub-id pub-id-type="pmid">22673542</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name><surname>Ben Haim</surname><given-names>L</given-names></name><etal/></person-group><article-title>The JAK/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer&#x02019;s and Huntington&#x02019;s diseases</article-title><source>J Neurosci</source><year>2015</year><volume>35</volume><issue>6</issue><fpage>2817</fpage><lpage>2829</lpage><pub-id pub-id-type="pmid">25673868</pub-id>
</element-citation><mixed-citation id="mc-CR52" publication-type="journal">Ben Haim L et al (2015) The JAK/STAT3 pathway is a common inducer of astrocyte reactivity in Alzheimer&#x02019;s and Huntington&#x02019;s diseases. J Neurosci 35(6):2817&#x02013;2829<pub-id pub-id-type="pmid">25673868</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Yarza</surname><given-names>R</given-names></name><etal/></person-group><article-title>c-Jun N-terminal kinase (JNK) signaling as a therapeutic target for Alzheimer&#x02019;s Disease</article-title><source>Front Pharmacol</source><year>2015</year><volume>6</volume><fpage>321</fpage><pub-id pub-id-type="pmid">26793112</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Yarza R et al (2015) c-Jun N-terminal kinase (JNK) signaling as a therapeutic target for Alzheimer&#x02019;s Disease. Front Pharmacol 6:321<pub-id pub-id-type="pmid">26793112</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Targeting estrogen receptors for the treatment of Alzheimer&#x02019;s disease</article-title><source>Mol Neurobiol</source><year>2014</year><volume>49</volume><issue>1</issue><fpage>39</fpage><lpage>49</lpage><pub-id pub-id-type="pmid">23771838</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Lee JH et al (2014) Targeting estrogen receptors for the treatment of Alzheimer&#x02019;s disease. Mol Neurobiol 49(1):39&#x02013;49<pub-id pub-id-type="pmid">23771838</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Romano</surname><given-names>R</given-names></name><name><surname>Bucci</surname><given-names>C</given-names></name></person-group><article-title>Role of EGFR in the nervous system</article-title><source>Cells</source><year>2020</year><volume>9</volume><issue>8</issue><fpage>1887</fpage><pub-id pub-id-type="pmid">32806510</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Romano R, Bucci C (2020) Role of EGFR in the nervous system. Cells 9(8):1887<pub-id pub-id-type="pmid">32806510</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Chitranshi</surname><given-names>N</given-names></name><etal/></person-group><article-title>PTPN11 induces endoplasmic stress and apoptosis in SH-SY5Y cells</article-title><source>Neuroscience</source><year>2017</year><volume>364</volume><fpage>175</fpage><lpage>189</lpage><pub-id pub-id-type="pmid">28947394</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Chitranshi N et al (2017) PTPN11 induces endoplasmic stress and apoptosis in SH-SY5Y cells. Neuroscience 364:175&#x02013;189<pub-id pub-id-type="pmid">28947394</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>S</given-names></name><etal/></person-group><article-title>Genomics and Drug Discovery Strategies: the role of natural compounds and its receptor in Alzheimer&#x02019;s Disease</article-title><source>Cureus</source><year>2024</year><volume>16</volume><issue>1</issue><fpage>e52423</fpage><pub-id pub-id-type="pmid">38371064</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Mishra S et al (2024) Genomics and drug discovery strategies: the role of natural compounds and its receptor in Alzheimer&#x02019;s disease. Cureus 16(1):e52423<pub-id pub-id-type="pmid">38371064</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Razani</surname><given-names>E</given-names></name><etal/></person-group><article-title>The PI3K/Akt signaling axis in Alzheimer&#x02019;s disease: a valuable target to stimulate or suppress?</article-title><source>Cell Stress Chaperones</source><year>2021</year><volume>26</volume><issue>6</issue><fpage>871</fpage><lpage>887</lpage><pub-id pub-id-type="pmid">34386944</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Razani E et al (2021) The PI3K/Akt signaling axis in Alzheimer&#x02019;s disease: a valuable target to stimulate or suppress? Cell Stress Chaperones 26(6):871&#x02013;887<pub-id pub-id-type="pmid">34386944</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Long</surname><given-names>HZ</given-names></name><etal/></person-group><article-title>PI3K/AKT Signal Pathway: a target of Natural products in the Prevention and Treatment of Alzheimer&#x02019;s Disease and Parkinson&#x02019;s Disease</article-title><source>Front Pharmacol</source><year>2021</year><volume>12</volume><fpage>648636</fpage><pub-id pub-id-type="pmid">33935751</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Long HZ et al (2021) PI3K/AKT signal pathway: a target of natural products in the prevention and treatment of Alzheimer&#x02019;s disease and Parkinson&#x02019;s disease. Front Pharmacol 12:648636<pub-id pub-id-type="pmid">33935751</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Feld</surname><given-names>M</given-names></name><etal/></person-group><article-title>Decrease of ERK/MAPK overactivation in prefrontal cortex reverses early memory deficit in a mouse model of Alzheimer&#x02019;s disease</article-title><source>J Alzheimers Dis</source><year>2014</year><volume>40</volume><issue>1</issue><fpage>69</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">24334722</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Feld M et al (2014) Decrease of ERK/MAPK overactivation in prefrontal cortex reverses early memory deficit in a mouse model of Alzheimer&#x02019;s disease. J Alzheimers Dis 40(1):69&#x02013;82<pub-id pub-id-type="pmid">24334722</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Extracellular signal-regulated kinase regulates microglial immune responses in Alzheimer&#x02019;s disease</article-title><source>J Neurosci Res</source><year>2021</year><volume>99</volume><issue>6</issue><fpage>1704</fpage><lpage>1721</lpage><pub-id pub-id-type="pmid">33729626</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Chen MJ et al (2021) Extracellular signal-regulated kinase regulates microglial immune responses in Alzheimer&#x02019;s disease. J Neurosci Res 99(6):1704&#x02013;1721<pub-id pub-id-type="pmid">33729626</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other">Tsai AP et al (2020) PLCG2 as a Risk Factor for Alzheimer&#x02019;s Disease. bioRxiv,: p. 2020.05. 19.104216</mixed-citation></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>AP</given-names></name><etal/></person-group><article-title>PLCG2 is associated with the inflammatory response and is induced by amyloid plaques in Alzheimer&#x02019;s disease</article-title><source>Genome Med</source><year>2022</year><volume>14</volume><issue>1</issue><fpage>17</fpage><pub-id pub-id-type="pmid">35180881</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Tsai AP et al (2022) PLCG2 is associated with the inflammatory response and is induced by amyloid plaques in Alzheimer&#x02019;s disease. Genome Med 14(1):17<pub-id pub-id-type="pmid">35180881</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name></person-group><article-title>Identification of dysregulated genes and pathways of different brain regions in Alzheimer&#x02019;s disease</article-title><source>Int J Neurosci</source><year>2020</year><volume>130</volume><issue>11</issue><fpage>1082</fpage><lpage>1094</lpage><pub-id pub-id-type="pmid">32019384</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Wang Y, Wang Z (2020) Identification of dysregulated genes and pathways of different brain regions in Alzheimer&#x02019;s disease. Int J Neurosci 130(11):1082&#x02013;1094<pub-id pub-id-type="pmid">32019384</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Y</given-names></name><etal/></person-group><article-title>miR-132 improves the cognitive function of rats with Alzheimer&#x02019;s disease by inhibiting the MAPK1 signal pathway</article-title><source>Exp Ther Med</source><year>2020</year><volume>20</volume><issue>6</issue><fpage>159</fpage><pub-id pub-id-type="pmid">33093897</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Deng Y et al (2020) miR-132 improves the cognitive function of rats with Alzheimer&#x02019;s disease by inhibiting the MAPK1 signal pathway. Exp Ther Med 20(6):159<pub-id pub-id-type="pmid">33093897</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Rusek</surname><given-names>M</given-names></name><etal/></person-group><article-title>The role of the JAK/STAT signaling pathway in the pathogenesis of Alzheimer&#x02019;s Disease: new potential treatment target</article-title><source>Int J Mol Sci</source><year>2023</year><volume>24</volume><issue>1</issue><fpage>864</fpage><pub-id pub-id-type="pmid">36614305</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Rusek M et al (2023) The role of the JAK/STAT signaling pathway in the pathogenesis of Alzheimer&#x02019;s disease: new potential treatment target. Int J Mol Sci 24(1):864<pub-id pub-id-type="pmid">36614305</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>DC</given-names></name><etal/></person-group><article-title>Histone acetylation in an Alzheimer&#x02019;s disease cell model promotes homeostatic amyloid-reducing pathways</article-title><source>Acta Neuropathol Commun</source><year>2024</year><volume>12</volume><issue>1</issue><fpage>3</fpage><pub-id pub-id-type="pmid">38167174</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Xu DC et al (2024) Histone acetylation in an Alzheimer&#x02019;s disease cell model promotes homeostatic amyloid-reducing pathways. Acta Neuropathol Commun 12(1):3<pub-id pub-id-type="pmid">38167174</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Mehan</surname><given-names>S</given-names></name><etal/></person-group><article-title>JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer&#x02019;s and various neurodegenerative abnormalities</article-title><source>J Mol Neurosci</source><year>2011</year><volume>43</volume><issue>3</issue><fpage>376</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">20878262</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Mehan S et al (2011) JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer&#x02019;s and various neurodegenerative abnormalities. J Mol Neurosci 43(3):376&#x02013;390<pub-id pub-id-type="pmid">20878262</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Perry</surname><given-names>RT</given-names></name><etal/></person-group><article-title>The role of TNF and its receptors in Alzheimer&#x02019;s disease</article-title><source>Neurobiol Aging</source><year>2001</year><volume>22</volume><issue>6</issue><fpage>873</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">11754994</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Perry RT et al (2001) The role of TNF and its receptors in Alzheimer&#x02019;s disease. Neurobiol Aging 22(6):873&#x02013;883<pub-id pub-id-type="pmid">11754994</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Takayama</surname><given-names>K-i</given-names></name><name><surname>Inoue</surname><given-names>S</given-names></name></person-group><article-title>Expression and function of estrogen receptors and estrogen-related receptors in the brain and their association with Alzheimer&#x02019;s disease</article-title><source>Front Endocrinol</source><year>2023</year><volume>14</volume><fpage>1220150</fpage></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Sato K, Takayama K-i, Inoue S (2023) Expression and function of estrogen receptors and estrogen-related receptors in the brain and their association with Alzheimer&#x02019;s disease. Front Endocrinol 14:1220150</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Louneva</surname><given-names>N</given-names></name><etal/></person-group><article-title>Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer&#x02019;s disease</article-title><source>Am J Pathol</source><year>2008</year><volume>173</volume><issue>5</issue><fpage>1488</fpage><lpage>1495</lpage><pub-id pub-id-type="pmid">18818379</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Louneva N et al (2008) Caspase-3 is enriched in postsynaptic densities and increased in Alzheimer&#x02019;s disease. Am J Pathol 173(5):1488&#x02013;1495<pub-id pub-id-type="pmid">18818379</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Amelio</surname><given-names>M</given-names></name><etal/></person-group><article-title>Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer&#x02019;s disease</article-title><source>Nat Neurosci</source><year>2011</year><volume>14</volume><issue>1</issue><fpage>69</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">21151119</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">D&#x02019;Amelio M et al (2011) Caspase-3 triggers early synaptic dysfunction in a mouse model of Alzheimer&#x02019;s disease. Nat Neurosci 14(1):69&#x02013;76<pub-id pub-id-type="pmid">21151119</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Ettcheto</surname><given-names>M</given-names></name><etal/></person-group><article-title>Early preclinical changes in hippocampal CREB-Binding protein expression in a mouse model of familial Alzheimer&#x02019;s Disease</article-title><source>Mol Neurobiol</source><year>2018</year><volume>55</volume><issue>6</issue><fpage>4885</fpage><lpage>4895</lpage><pub-id pub-id-type="pmid">28752224</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Ettcheto M et al (2018) Early preclinical changes in hippocampal CREB-Binding protein expression in a mouse model of familial Alzheimer&#x02019;s disease. Mol Neurobiol 55(6):4885&#x02013;4895<pub-id pub-id-type="pmid">28752224</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Pao</surname><given-names>PC</given-names></name><etal/></person-group><article-title>HDAC1 modulates OGG1-initiated oxidative DNA damage repair in the aging brain and Alzheimer&#x02019;s disease</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>2484</fpage><pub-id pub-id-type="pmid">32424276</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Pao PC et al (2020) HDAC1 modulates OGG1-initiated oxidative DNA damage repair in the aging brain and Alzheimer&#x02019;s disease. Nat Commun 11(1):2484<pub-id pub-id-type="pmid">32424276</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>BJ</given-names></name><etal/></person-group><article-title>ErbB2 regulates autophagic flux to modulate the proteostasis of APP-CTFs in Alzheimer&#x02019;s disease</article-title><source>Proc Natl Acad Sci U S A</source><year>2017</year><volume>114</volume><issue>15</issue><fpage>E3129</fpage><lpage>E3138</lpage><pub-id pub-id-type="pmid">28351972</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Wang BJ et al (2017) ErbB2 regulates autophagic flux to modulate the proteostasis of APP-CTFs in Alzheimer&#x02019;s disease. Proc Natl Acad Sci U S A 114(15):E3129&#x02013;E3138<pub-id pub-id-type="pmid">28351972</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Tolar</surname><given-names>M</given-names></name><etal/></person-group><article-title>Neurotoxic soluble amyloid oligomers drive Alzheimer&#x02019;s pathogenesis and represent a clinically validated target for slowing disease progression</article-title><source>Int J Mol Sci</source><year>2021</year><volume>22</volume><issue>12</issue><fpage>6355</fpage><pub-id pub-id-type="pmid">34198582</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Tolar M et al (2021) Neurotoxic soluble amyloid oligomers drive Alzheimer&#x02019;s pathogenesis and represent a clinically validated target for slowing disease progression. Int J Mol Sci 22(12):6355<pub-id pub-id-type="pmid">34198582</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Carbon monoxide attenuates amyloidogenesis via down-regulation of NF-kappaB-mediated BACE1 gene expression</article-title><source>Aging Cell</source><year>2019</year><volume>18</volume><issue>1</issue><fpage>e12864</fpage><pub-id pub-id-type="pmid">30411846</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">Kim HJ et al (2019) Carbon monoxide attenuates amyloidogenesis via down-regulation of NF-kappaB-mediated BACE1 gene expression. Aging Cell 18(1):e12864<pub-id pub-id-type="pmid">30411846</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR78"><label>78.</label><citation-alternatives><element-citation id="ec-CR78" publication-type="journal"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>H</given-names></name><etal/></person-group><article-title>Resveratrol attenuates radiation enteritis through the SIRT1/FOXO3a and PI3K/AKT signaling pathways</article-title><source>Biochem Biophys Res Commun</source><year>2021</year><volume>554</volume><fpage>199</fpage><lpage>205</lpage><pub-id pub-id-type="pmid">33812084</pub-id>
</element-citation><mixed-citation id="mc-CR78" publication-type="journal">Qin H et al (2021) Resveratrol attenuates radiation enteritis through the SIRT1/FOXO3a and PI3K/AKT signaling pathways. Biochem Biophys Res Commun 554:199&#x02013;205<pub-id pub-id-type="pmid">33812084</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR79"><label>79.</label><citation-alternatives><element-citation id="ec-CR79" publication-type="journal"><person-group person-group-type="author"><name><surname>Maiese</surname><given-names>K</given-names></name></person-group><article-title>Targeting the core of neurodegeneration: FoxO, mTOR, and SIRT1</article-title><source>Neural Regen Res</source><year>2021</year><volume>16</volume><issue>3</issue><fpage>448</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">32985464</pub-id>
</element-citation><mixed-citation id="mc-CR79" publication-type="journal">Maiese K (2021) Targeting the core of neurodegeneration: FoxO, mTOR, and SIRT1. Neural Regen Res 16(3):448&#x02013;455<pub-id pub-id-type="pmid">32985464</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR80"><label>80.</label><citation-alternatives><element-citation id="ec-CR80" publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>P</given-names></name><etal/></person-group><article-title>Protective role of Dihydromyricetin in Alzheimer&#x02019;s disease rat model associated with activating AMPK/SIRT1 signaling pathway</article-title><source>Biosci Rep</source><year>2019</year><volume>39</volume><issue>1</issue><fpage>BSR20180902</fpage><pub-id pub-id-type="pmid">30498091</pub-id>
</element-citation><mixed-citation id="mc-CR80" publication-type="journal">Sun P et al (2019) Protective role of Dihydromyricetin in Alzheimer&#x02019;s disease rat model associated with activating AMPK/SIRT1 signaling pathway. Biosci Rep 39(1):BSR20180902<pub-id pub-id-type="pmid">30498091</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR81"><label>81.</label><citation-alternatives><element-citation id="ec-CR81" publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>WJ</given-names></name><etal/></person-group><article-title>AMPKalpha1 overexpression improves postoperative cognitive dysfunction in aged rats through AMPK-Sirt1 and autophagy signaling</article-title><source>J Cell Biochem</source><year>2019</year><volume>120</volume><issue>7</issue><fpage>11633</fpage><lpage>11641</lpage><pub-id pub-id-type="pmid">30775803</pub-id>
</element-citation><mixed-citation id="mc-CR81" publication-type="journal">Yan WJ et al (2019) AMPKalpha1 overexpression improves postoperative cognitive dysfunction in aged rats through AMPK-Sirt1 and autophagy signaling. J Cell Biochem 120(7):11633&#x02013;11641<pub-id pub-id-type="pmid">30775803</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR82"><label>82.</label><citation-alternatives><element-citation id="ec-CR82" publication-type="journal"><person-group person-group-type="author"><name><surname>Khan</surname><given-names>RS</given-names></name><etal/></person-group><article-title>SIRT1 activating compounds reduce oxidative stress and prevent cell death in neuronal cells</article-title><source>Front Cell Neurosci</source><year>2012</year><volume>6</volume><fpage>63</fpage><pub-id pub-id-type="pmid">23293585</pub-id>
</element-citation><mixed-citation id="mc-CR82" publication-type="journal">Khan RS et al (2012) SIRT1 activating compounds reduce oxidative stress and prevent cell death in neuronal cells. Front Cell Neurosci 6:63<pub-id pub-id-type="pmid">23293585</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR83"><label>83.</label><citation-alternatives><element-citation id="ec-CR83" publication-type="journal"><person-group person-group-type="author"><name><surname>Benek</surname><given-names>O</given-names></name><name><surname>Korabecny</surname><given-names>J</given-names></name><name><surname>Soukup</surname><given-names>O</given-names></name></person-group><article-title>A perspective on multi-target drugs for Alzheimer&#x02019;s disease</article-title><source>Trends Pharmacol Sci</source><year>2020</year><volume>41</volume><issue>7</issue><fpage>434</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">32448557</pub-id>
</element-citation><mixed-citation id="mc-CR83" publication-type="journal">Benek O, Korabecny J, Soukup O (2020) A perspective on multi-target drugs for Alzheimer&#x02019;s disease. Trends Pharmacol Sci 41(7):434&#x02013;445<pub-id pub-id-type="pmid">32448557</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR84"><label>84.</label><citation-alternatives><element-citation id="ec-CR84" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><etal/></person-group><article-title>Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer&#x02019;s disease</article-title><source>Eur J Med Chem</source><year>2019</year><volume>169</volume><fpage>200</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">30884327</pub-id>
</element-citation><mixed-citation id="mc-CR84" publication-type="journal">Wang T et al (2019) Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer&#x02019;s disease. Eur J Med Chem 169:200&#x02013;223<pub-id pub-id-type="pmid">30884327</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR85"><label>85.</label><citation-alternatives><element-citation id="ec-CR85" publication-type="journal"><person-group person-group-type="author"><name><surname>Chiba</surname><given-names>T</given-names></name><name><surname>Yamada</surname><given-names>M</given-names></name><name><surname>Aiso</surname><given-names>S</given-names></name></person-group><article-title>Targeting the JAK2/STAT3 axis in Alzheimer&#x02019;s disease</article-title><source>Expert Opin Ther Targets</source><year>2009</year><volume>13</volume><issue>10</issue><fpage>1155</fpage><lpage>1167</lpage><pub-id pub-id-type="pmid">19663649</pub-id>
</element-citation><mixed-citation id="mc-CR85" publication-type="journal">Chiba T, Yamada M, Aiso S (2009) Targeting the JAK2/STAT3 axis in Alzheimer&#x02019;s disease. Expert Opin Ther Targets 13(10):1155&#x02013;1167<pub-id pub-id-type="pmid">19663649</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR86"><label>86.</label><citation-alternatives><element-citation id="ec-CR86" publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>M</given-names></name><etal/></person-group><article-title>Role of JAK/STAT in the Neuroinflammation and its Association with Neurological disorders</article-title><source>Ann Neurosci</source><year>2021</year><volume>28</volume><issue>3&#x02013;4</issue><fpage>191</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">35341232</pub-id>
</element-citation><mixed-citation id="mc-CR86" publication-type="journal">Jain M et al (2021) Role of JAK/STAT in the neuroinflammation and its association with neurological disorders. Ann Neurosci 28(3&#x02013;4):191&#x02013;200<pub-id pub-id-type="pmid">35341232</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR87"><label>87.</label><citation-alternatives><element-citation id="ec-CR87" publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>EK</given-names></name><name><surname>Choi</surname><given-names>EJ</given-names></name></person-group><article-title>Pathological roles of MAPK signaling pathways in human diseases</article-title><source>Biochim Biophys Acta</source><year>2010</year><volume>1802</volume><issue>4</issue><fpage>396</fpage><lpage>405</lpage><pub-id pub-id-type="pmid">20079433</pub-id>
</element-citation><mixed-citation id="mc-CR87" publication-type="journal">Kim EK, Choi EJ (2010) Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802(4):396&#x02013;405<pub-id pub-id-type="pmid">20079433</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR88"><label>88.</label><citation-alternatives><element-citation id="ec-CR88" publication-type="journal"><person-group person-group-type="author"><name><surname>Munoz</surname><given-names>L</given-names></name><name><surname>Ammit</surname><given-names>AJ</given-names></name></person-group><article-title>Targeting p38 MAPK pathway for the treatment of Alzheimer&#x02019;s disease</article-title><source>Neuropharmacology</source><year>2010</year><volume>58</volume><issue>3</issue><fpage>561</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">19951717</pub-id>
</element-citation><mixed-citation id="mc-CR88" publication-type="journal">Munoz L, Ammit AJ (2010) Targeting p38 MAPK pathway for the treatment of Alzheimer&#x02019;s disease. Neuropharmacology 58(3):561&#x02013;568<pub-id pub-id-type="pmid">19951717</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR89"><label>89.</label><citation-alternatives><element-citation id="ec-CR89" publication-type="journal"><person-group person-group-type="author"><name><surname>Jiao</surname><given-names>F</given-names></name><name><surname>Gong</surname><given-names>Z</given-names></name></person-group><article-title>The beneficial roles of SIRT1 in Neuroinflammation-Related diseases</article-title><source>Oxid Med Cell Longev</source><year>2020</year><volume>2020</volume><fpage>6782872</fpage><pub-id pub-id-type="pmid">33014276</pub-id>
</element-citation><mixed-citation id="mc-CR89" publication-type="journal">Jiao F, Gong Z (2020) The beneficial roles of SIRT1 in neuroinflammation-related diseases. Oxid Med Cell Longev 2020:6782872<pub-id pub-id-type="pmid">33014276</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR90"><label>90.</label><citation-alternatives><element-citation id="ec-CR90" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C</given-names></name><etal/></person-group><article-title>SIRT1 and aging related signaling pathways</article-title><source>Mech Ageing Dev</source><year>2020</year><volume>187</volume><fpage>111215</fpage><pub-id pub-id-type="pmid">32084459</pub-id>
</element-citation><mixed-citation id="mc-CR90" publication-type="journal">Chen C et al (2020) SIRT1 and aging related signaling pathways. Mech Ageing Dev 187:111215<pub-id pub-id-type="pmid">32084459</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>